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Abstract 
 
Background: Rheumatic heart disease (RHD) is a progressive chronic health condition 
characterised by damaged heart valves and predominantly occurs in younger adults in 
low- and middle- income countries (LMICs). Replacement of the damaged heart valve/s 
improves patient outcomes, however mechanical valves are often used in LMIC, so 
ongoing medical monitoring and self-care are required. The Fiji Islands is a LMIC with 
one of the highest rates of RHD in the world and valve replacement (VR) is often 
undertaken by humanitarian fly-in/fly-out surgical teams. Open Heart International 
(OHI), is one such team, which has been conducting VR surgery for RHD in Fiji since 
1991.  
Aims: Identify the short and long-term outcomes of mechanical VR surgery for RHD in 
Fiji since 1991. Specifically: 1) Determine the mortality and morbidity outcomes and 
identify independent predictors of these outcomes; 2a) Determine what is globally known 
about the HRQoL of younger mechanical VR patients through an integrative literature 
review; 2b) Determine pre-and post-operative HRQoL of patients who have VR surgery 
by OHI and identify independent predictors of these outcomes; and, 3) Determine 
anticoagulation adherence and predictors of non-adherence of patients who had VR 
surgery by OHI.     
Methods: 1) Morbidity and mortality data were collected through medical record audit on 
all patients (n = 167) with records available on mortality for 149 (89.2% patients, and 
morbidity for 152 (91%) patients. 2a) A systematic search of the electronic bibliographic 
databases OVIDMedline, PyscINFO(OVID), PubMED, CINAHL(EBSCO), ProQuest 
Health & Medicine, Cochrane Library(Wiley), and Google Scholar for studies published 
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between January 2000 and April 2013 was undertaken on HRQoL outcomes post 
mechanical VR in patients aged < 65 years. 2b) a cross-sectional study of HRQoL was 
undertaken of patients who had surgery from 1991–2009 (n = 72) and pre- and/or post-
operatively (mean follow-up time 5.9 years) in patients undergoing surgery from 2010-
2013 (n = 56) using the standard SF-36 (v2) survey. 3) Aspects of antithrombotic health 
self-management were evaluated using a cross-sectional survey study. 
Results: 1) Patients who underwent VR surgery had a mean age of 26 years at time of 
operation and incurred 26% mortality and morbidity rates over the 20-year follow-up 
period. Half of all mortality and a quarter of all morbidity occurred in the first year 
postoperatively, with the major causes of both being related to anticoagulation and an 
absence of RHD-prophylaxis. Females required more hospital admissions for heart 
failure, were significantly more vulnerable to major adverse outcomes including bleeding 
and cerebral events, and were three times more likely to die prematurely. 2a) The 
systematic literature review indicated that post-VR surgery individuals can expect 
sustained and improved HRQoL, although lower HRQoL occurred in younger people, 
and those in resource-limited regions. Aspects of valve-specific health self-management 
requirements were identified as potentially impairing HRQoL. 2b) Overall HRQoL 
outcomes improved substantially for the majority of individuals. A clinically significant 
decline in mental health domains occurred at one year; domains related to physicality and 
emotional health significantly declined at two years; and overall, males were 
independently at risk of impairment in emotional health. 3) Ongoing medical support 
issues were evident, with more than two-thirds of younger adults not commenced/re-
commenced on postoperative RHD prophylaxis, a quarter reported poor adherence to 
their warfarin regime, and 13.38% (n=17) had self-ceased warfarin completely. Younger 
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age was strongly associated with poor adherence to warfarin; however, lack of 
knowledge, routinely forgetting to take warfarin, and a longer travel time to the heart 
clinic was strongly associated with eventual complete self-cessation of warfarin. 
Conclusions: This research highlights the important role of fly-in/fly-out teams in 
providing VR surgery for people affected by RHD in the LMIC of Fiji. Whilst there 
appeared to be substantial and ongoing benefits in terms of mortality, morbidity and 
HRQoL, there were subsets of people who experienced suboptimal outcomes. The need 
for increased surveillance, targeted preoperative education and continued and evolving 
postoperative education was clearly identified. Being a resource-limited country, a 
sustainable source of funding is unlikely in the short term, and therefore exploring ways 
that existing health professionals, such as nurses, could be better utilised for increased 
patient surveillance, support and education is indicated. Engagement with Ministry of 
Health and the wider medical and nursing workforce is necessary to ensure that once the 
surgical team departs, these young people remain prioritised. Further research is needed 
to identify reasons for disparities in gender outcomes and strategies to address this.   
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Rationale and Context  
Worldwide, cardiovascular diseases (CVD) remain the leading cause of death and disability 
(Mair et al., 2012; Vos et al., 2016; WHO, 2017). Within this disease classification, valvular 
heart disease is becoming increasingly important (Celermajer, Chow, Marijon, Anstey, & Woo, 
2012), (Farrar & Butcher, 2012). Valvular heart disease has numerous causes, including 
degenerative calcific changes over time and rheumatic, congenital and infectious aetiologies 
(Iung et al., 2003; Otto & Bonow, 2012). The valvular pathology leading to the need for valve 
replacement (VR) surgery differs markedly between low- and middle-income countries (LMICs) 
and high-income countries (HICs) (Carapetis, 2007; Carapetis, 2008; Carapetis, Currie, & 
Kaplan, 1999; Carapetis, Steer, Mulholland, & Weber, 2005; Samiei et al., 2014). In HICs, 
changes associated with ageing are the cause of degenerative valvular heart disease in older 
adults and thus, the prevalence increases with an ageing population (Gordis, 1985). In the HIC 
context, VR surgery accounts for more than 20% of all cardiac procedures undertaken annually 
(Allareddy, Ward, Ely, & Levett, 2007; Nkomo et al., 2006). In contrast, in LMICs, valvular 
heart disease occurs most often in children, adolescents and younger adults, due to endemic 
rheumatic heart disease (RHD) (Carapetis, 2007; Carapetis, 2008; Carapetis et al., 1999; 
Carapetis et al., 2005).  
The pathogenesis of rheumatic heart disease.   
RHD is an entirely preventable and treatable chronic condition. Yet, despite this, RHD 
affects an estimated 33 million people globally (Celermajer et al., 2012; Vos et al., 2016; WHO, 
2004). RHD is a disease of the disadvantaged, with approximately 80% of people who have 
RHD living in LMICs, or are indigenous and/or immigrant people in HICs (Carapetis et al., 
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2005; Celermajer et al., 2012; Nulu, Bukhman, & Kwan, 2017; Rothenbuhler et al., 2014; WHO, 
2004). RHD has become the most common cause of acquired cardiovascular morbidity and 
mortality amongst children, adolescents, and younger adults, particularly pregnant women.  
RHD is the cumulative endpoint of acute rheumatic fever (ARF), which in turn results 
from untreated Group A streptococcus (GAS) pharyngitis (WHO, 2004). Whilst GAS 
pharyngitis is common during childhood, if untreated and in a susceptible host, a GAS infection 
may initiate an abnormal auto-immune response resulting in an episode of ARF (WHO, 2004). 
ARF manifests with a range of transient symptomology including fever, migratory and/or mono-
arthritis, inflammation of major joints, erythema marginatum and chest pain, but it is the effects 
of the auto-immune response that causes permanent damage to the structure of heart valves 
(Carapetis et al., 2006; WHO, 2004). This structural damage evidences as valvular scarring, or 
lesion formation, defines RHD (Carapetis et al., 2006; WHO, 2004).  
GAS infections are readily treated with Benzathine Penicillin-G (BPG), which, when 
instigated early, prevents progression to ARF (primary prevention) (WHO, 2004). However, 
childhood pharyngitis may not be identified as a serious concern and, in LMICs, infrequently 
diagnosed or treated (WHO, 2004). If a GAS infection progresses to ARF, many of the 
symptoms of ARF, such as arthralgia and fever, are difficult to distinguish from common 
childhood/adolescent aches and pains potentially reducing treatment-seeking behaviours (Walsh 
et al., 2008; WHO, 2004; Wyber et al., 2014). Early identification of ARF enables timely 
treatment so that the valvular lesions of RHD can be avoided, or minimised, by regular 
administration of a prophylactic regime of BPG until adulthood (secondary prevention) (Walsh 
et al., 2008; Wyber, Taubert, Marko, & Kaplan, 2013). 
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Barriers to early diagnosis. RHD is not curable and often remains undetected until the 
person experiences heart failure or stroke, or symptoms and signs are identified during a routine 
exam for other purposes, such as antenatal screening (Wyber et al., 2013). The most common 
barriers to detection and optimal prophylaxis for RHD relate to inequities in health service access 
and fluctuations in BPG supply and access (WHO, 2004; World Heart Federation and WHO, 
2007; Wyber et al., 2013). Thus, health inequities also contribute to large numbers of younger 
adults affected by RHD having a compromised and shorter life (Wyber et al., 2014; Wyber et al., 
2013). Consequently, for many LMICs, a disproportionate number of health-system budgets are 
consumed in treating those with RHD and tertiary treatments such as valve replacement (VR) 
surgery rather than the more cost-effective primary and secondary prevention (Markbreiter, 
2016; WHO, 2004; World Heart Federation and WHO, 2007; Wyber et al., 2013).  
Access to valve replacement surgery.  
In HICs and better-resourced countries, people affected by RHD are able to access 
tertiary treatments such as valve surgery at regional and tertiary referral hospitals (Lawrence, 
Carapetis, Griffiths, Edwards, & Condon, 2013; Mirabel et al., 2015). However, the majority of 
people affected by RHD live in less resourced regions of the world, and for most, high-level 
expertise and/or facilities for valve surgery are either non-existent, difficult to access and/or are 
cost prohibitive (Davis, Wainer, O'Keefe, & Nand, 2011; Mirabel et al., 2015; Okello, 
Longenecker, Beaton, Kamya, & Lwabi, 2017; Sliwa et al., 2010; Tefuarani et al., 2007; Zühlke 
et al., 2015). One solution has been for HICs to sponsor volunteer surgical teams to LMICs and 
this is the case in the South Pacific.  
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Fly-in/fly-out cardiothoracic surgical team services.  
South Pacific Island countries such as Vanuatu, Tonga, the Solomon Islands and the Fiji 
Islands, exemplify a region without in-country, cardiac surgical services for RHD and thus 
limited treatment options (Davis et al., 2011; Tefuarani et al., 2007). In these countries, small 
numbers of patients requiring timely rheumatic valve replacement and repair surgery can be sent 
to neighbouring well-resourced countries for treatment using government funding, and/or under 
schemes such as the Overseas Referrals Scheme (ORS), a branch of the New Zealand Medical 
Treatment Scheme cases (Health Specialists Limited). The ORS has very narrow eligibility 
criteria and is used for only the most urgent cases (Health Specialists Limited). The ORS funds 
treatment in New Zealand or Australia with the participating referring country paying for airfares 
and patient-support costs (Health Specialists Limited). Volunteer cardiothoracic surgical teams 
may provide a solution, but such teams must be invited in-country to perform surgery by the 
government of the host country, so longevity and continuity of access is never assured (Davis et 
al., 2011; Tefuarani et al., 2007; Viali, Saena, & Futi, 2011).  
When VR surgery for RHD is undertaken by volunteer teams in-country, the capacity to 
treat affected patients is substantially enhanced and reduces the burden on the host-country’s 
Ministry of Health (MoH). Substantial benefits also accrue for patients who receive treatment not 
only in terms of reduced mortality, morbidity and symptoms but also during treatment they 
benefit from proximity to their extended family, familiar language, foods, customs, and culture.  
Open Heart International. Open Heart International (OHI, formerly Operation Open 
Heart) is an Australian-based, international aid organisation that was set up in 1985 to organise 
and coordinate volunteer fly-in/fly-out in-country missions to provide specialised surgical 
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services otherwise unavailable in host countries. One arm of OHI is focused on cardiac surgical 
services providing surgery for congenital heart disorders and for people with valvular damage 
from RHD. All missions start with an invitation from the host countries’ government. Thereafter, 
volunteers organise their own leave and pay a pre-set minimum amount ranging from AU$1800 
to AU$4000 varying according to destination with funds contributing to the team costs and 
operative consumables. 
Open Heart International (OHI) has including annual cardiothoracic missions to Fiji since 
1990 (Open Heart International, 2017). To date, OHI has performed more than 800 
cardiothoracic surgical procedures in Fiji alone. Volunteers in this team take personal leave and 
pay a minimum fixed sum-contribution to fund medical disposables, travel and accommodation 
(Open Heart International, 2017). Despite these quantifiable costs, substantial benefits also 
accrue to volunteers. OHI focus is on capacity building and skills transfer which, for many 
volunteers necessitates being outside their comfort zone, operating in regions that demand 
adaptability, leadership, lateral thinking and problem-solving skills at a level not ordinarily 
encountered at home in order to deliver HIC care with LMIC resources. Additional benefits 
encompass a sense of pride and satisfaction that arises through volunteer service to others, 
building personal relationships with patients and staff, a deeper understanding of the lives lived 
by people with less advantages, and appreciation of, and gratitude for, home health systems.  
The impact of limited resources in cardiac valve selection.  
Prosthetic valves are expensive. Although commercial, 'in-confidence' arrangements are 
often negotiated so that manufacturers provide these at greatly reduced costs, the host-country’s 
MoH is responsible for the funding of the prosthetic valves.  The selection of prosthetic valves 
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therefore must be carefully considered in terms of the host country’s capacity to pay, the cost of 
future replacements and the benefits and risks for the recipients, which are complex in the RHD 
context. For instance, biological valves are only considered for women of childbearing age and 
those in remote regions, because despite being less durable than mechanical valves, there is a far 
lower risk of stroke and/or bleeding in a context where warfarin treatment is harder to manage.  
Most MoH will only fund the costs of valve/s for an initial replacement and thus the 
burden of funding further replacements lies with the patient. Use of bioprosthetic valves is 
further constrained by the accelerated degeneration that occurs when these are implanted in 
younger patients (Henaine, Roubertie, Vergnat, & Ninet, 2012; Saleeb et al.). Consequently, in 
LMICs, the majority of prostheses implanted are mechanical and thus for the recipients create a 
cascade of lifelong health care and self-care requirements (Akhtar et al., 2011; Henaine et al., 
2012; Samiei et al., 2014; Zühlke et al., 2015).  
The reality of using thrombogenic mechanical valves to replace RHD damaged valves in 
the context of LMICs and volunteer surgical teams is that the surgery is expected to improve 
survival and quality-of-life for most people but will also introduce a requirement for a high level 
of health self-management and medical surveillance (Altiok, Yilmaz, & Rencüsoğullari, 2015; 
Corbi, Dantas, Pelegrino, & Carvalho, 2011; Davis, Billett, Cohen, & Arnsten, 2005; Kneeland 
& Fang, 2010). When mechanical valves are implanted in younger people there is greater 
complexity because younger people have additional developmental life-stage pressures and have 
a longer lifespan through which to navigate anti-thrombotic management and other aspects of 
RHD treatment (Davis et al., 2005; Durkin, 2005; Henaine et al., 2012; Turkel & Pao, 2007).   
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Requirement for life-long anti-thrombotic therapy.  
Thrombi, such as those that form on mechanical valves, are created from fibrin and 
platelets with fibrin acting as a mesh to trap red blood cells which platelets then clump onto 
(Dangas, Weitz, Giustino, Makkar, & Mehran, 2016; Roudaut, Serri, & Lafitte, 2007). Anti-
thrombotic agents are classified as either anticoagulants or anti-platelet (Dangas et al., 2016). 
The only agent proven to be effective in preventing mechanical valve thrombus and emboli is 
warfarin, a vitamin K antagonist (Butchart et al., 2005; Dangas et al., 2016; Nishimura et al., 
2017). Whilst warfarin is highly effective it has a very narrow therapeutic window and a highly 
variable, intra-patient, anticoagulation effect, necessitating close medical surveillance of 
International Normalised Ratio (INR) testing and dosage titration (Ansell et al., 2004; Butchart et 
al., 2005; Leiria et al., 2011; Nishimura et al., 2017; Roudaut et al., 2007).  Intensifying the 
requirement for close medical surveillance, there are numerous factors that potentiate, or inhibit 
warfarin responsiveness across the spectrum of medications, plant and herb food sources, 
hypermetabolic states, weight-loss regimes, to alcohol intake and comorbidities that impair 
hepatic function, such as in congestive cardiac failure (Ansell et al., 2004; Kneeland & Fang, 
2010; Kulik et al., 2006; Leiria et al., 2011; Lip & Douketis, 2017). The mechanical valve 
recipient acquires complex lifestyle implications with prosthesis implantation, particularly 
restrictions in the domains of reproduction, sporting and leisure activities: these will be expanded 
upon in Chapter Two (Tillquist & Maddox, 2011; Walsh et al., 2008).  
Additional health considerations.  
Additional considerations for people affected by RHD are the heightened risk for 
infective endocarditis (IE) and the potential for RHD recurrence. IE is a serious acquired cardiac 
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disease with more than 30% of people dying within the first year from diagnosis (Karchmer, 
2012; Nkomo, 2007; Thuny, Grisoli, Collart, Habib, & Raoult, 2012). The combination of RHD 
and implantation of a mechanical valve greatly accentuates the risk (Baskerville et al., 2012; 
Karchmer, 2012; Nkomo, 2007; Thuny et al., 2012). People with prosthetic valves remain 
categorised as those at 'highest risk of adverse outcomes' from IE (Karchmer, 2012; Nishimura et 
al., 2017; Wilson et al., 2008). Consequently, penetrative dental procedures, incision or biopsy of 
the respiratory tract, non-elective urinary tract procedures, any procedures involving infected 
skin, skin structure or musculoskeletal tissue, amongst others, all require IE prophylaxis 
(Nishimura et al., 2017; Wilson et al., 2008). Vigilance and attention to oral health is also 
essential to prevent 'bacterial seeding' and includes annual dental checks for RHD valve 
recipients (Nishimura et al., 2017; Wilson et al., 2008). 
In RHD endemic regions, RHD prophylaxis is a lifelong requirement, even after valvular 
interventions, regardless if it is a VR or repair (Al-Jazairi et al., 2017; Walsh et al., 2008; Wyber 
et al., 2014). Previous guidelines had recommended remaining on four-weekly IMI BPG until the 
age of 40 post-valve surgery but there has been a shift in recent years with some authors and 
guidelines advocating for lifelong secondary prophylaxis (Al-Jazairi et al., 2017; Walsh et al., 
2008; Wyber et al., 2014; Zühlke et al., 2015).  
With the well-known challenges of warfarin adherence (Skeppholm & Friberg, 2014; 
Van Damme, Van Deyk, Budts, Verhamme, & Moons, 2011; Waterman et al., 2004), patients 
struggle to adhere to medication regimens (Sabaté, 2003; Wong et al., 2014). Further challenges 
occur during bridging anticoagulation to major surgery and the perceived burden of lifelong 
medical surveillance (Corbi et al., 2011; Oterhals, Fridlund, Nordrehaug, Haaverstad, & 
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Norekval, 2013) (Kneeland & Fang, 2010; Orensky & Holdford, 2005).  
In summary, RHD patients, particularly adolescents and younger mechanical valve 
recipients in LMICs and lesser resourced regions, face a lifetime in which to live with anti-
thrombotic management issues and adherence challenges complicated by additional health self-
management requirements of IE and RHD prophylaxis. However, little is known about the 
longer-term outcomes of mechanical valve replacement surgery for younger adults, particularly 
in countries without in-situ cardiothoracic surgical specialist services to manage their lifelong 
health-care needs.  
The Fiji Islands is a country without such in-situ services, yet Fijian people have one of 
the highest rates of RHD in the world and cardiac surgery to replace the RHD-damaged heart 
valves is often necessary (Steer, Carapetis, Nolan, & Shann, 2002; Steer, Jenney, et al., 2009; 
Steer, Kado, et al., 2009; WHF WHO, 2007). Additionally, disease progression is particularly 
rapid, with children as young as six years of age having RHD as the primary cause of death on 
autopsy (Singh, Carapetis, Buadromo, Samberkar, & Steer, 2008). 
The Fijian MoH has utilised the OHI cardiothoracic fly-in/fly-out surgical service 
annually since 1990, with VR surgery being performed from 1991. Therefore, this study set out 
to investigate the health-related outcomes for Fijian people who have undergone VR surgery to 
correct valves damaged from RHD from 1991 through to 2012.   
Personal Perspective  
I first became involved with volunteer, cardiothoracic, surgical services, fly-in/fly-out 
teams in 1999. I was asked to fill in as a last-minute intensive care unit (ICU) coordinator with 
OHI on a mission to Vanuatu. That inaugural trip to Vanuatu was followed by annual and/or bi-
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annual missions to various countries including Vietnam, Fiji and Tonga. It was Fiji that captured 
my heart and in 2001, I took over as the ICU coordinator which involved organising the packing 
of freight and supplies, working within, and managing of, the ICU team.  
In the earlier years, many of the RHD people we operated on were at the end stages of 
their disease process, severely incapacitated, and without any financial recourse to seek surgery 
overseas. It was a wonderful feeling, knowing and seeing first-hand the difference we were 
making to people's lives. However, as I walked to and from 'work' everyday, through the crowds 
waiting at the Special Outpatient Clinics (SOPD), I began to wonder about what 'happened after'. 
On paper and in reality it sounded straightforward: we were meeting OHI goals in terms of 
capacity building, training, and the provision of medical care unavailable in-country irrespective 
of race or religion. We formally handed care back to the local team and that handover was 
thorough and collaborative, involving the medical and nursing staff we had worked alongside for 
the preceding weeks. Additionally, detailed reports including numbers screened, surgeries 
performed, funding and budget, and standard mortality and morbidity data were submitted to the 
Fijian MoH, the Australian Royal College of Surgeons and the OHI board. 
However, the more trips I went on, and the more familiar I became with the routines and 
process of the Fijian health system, the more it troubled me that formal follow-up was only the 
required standard 30-day mortality and morbidity reports and the more questions I had 
surrounding the concept of  'handing back care' . Evolving relationships with local staff and 
returning patients led me to question 'what happens after'. Every visit medical staff would tell me 
that there was something unusual about Fijian patients because their INR's were particularly 
difficult to keep within TR. Wanting to know longer-term outcomes of our RHD mechanical VR 
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patients was of particular interest for me because many were young adolescents yet had acquired 
lifelong anticoagulation requirements in a country with limited resources.   
Additional concerns articulated by medical and nursing staff included VR patients and/or 
their families believing they were ‘cured’ and consequently not adhering to medication and/or 
anticoagulation use and not returning to the clinic for regular check-ups. There was (and 
remains) a lack of formalised follow-up process for contacting adult patients (16 years or older) 
if a SOPD clinic is missed. Whereas other patients, whilst adherent to clinic and cardiac 
medications,  had never returned to work or school, with parents and/or extended family and/or 
the patients themselves explaining they now needed to be 'kept safe' so staying home was 'best'.  
It became clear to me that we (the OHI team) needed to have a better understanding of 
what was happening to our patients once they went home/we left, in order to explore ways to 
provide education and discharge information specific their life-stage and the country they lived 
in.  Consequently, in 2005, I formally met with the then OHI coordinator Mrs Annette Baldwin 
to discuss what I felt was a need to create a database to record patient outcomes for existing and 
future patients.  Mrs Baldwin had been involved with Fiji OHI from its 1990 inception and was 
the keeper of the OHI records. Approval was given to access and consolidate the existing OHI 
Fiji paper patient operation-records and to continue to manage this data on an ongoing basis 
alongside my ICU coordinator role during Fiji missions. I met with the medical and nursing 
administrators at the hospital where the team operates OHI in Fiji, and obtained verbal and 
written approval for ongoing Fiji OHI electronic, operative and demographic data collation. The 
OHI Fiji database took me just over a year to create from the OHI archival paper records.  This 
database would prove invaluable when I finally enrolled in my PhD program in January 2008.  
13 
 
Thesis Aims 
The implantation of mechanical valve prostheses to replace valves damaged by RHD is 
accompanied by risks inherent to the disease, arising from the valve and the associated lifetime 
antithrombotic management requirements. When VR surgery occurs during adolescence and 
younger adulthood, the increased time living with the valve along with managing/prioritising 
health requirements across a greater range of life events such as completing school, finding a 
vocation and/or gaining an education, dating, marriage, and parenthood are likely to increase the 
need for specialised support and follow-up. An additional layer of complexity is also likely to be 
present when the people affected live in lesser-resourced countries such as Fiji, without 
specialised in-country surgical expertise, and where accessing routine health services may 
present further challenges. However, little is known on this topic. 
The overarching aim of the research presented in this thesis was to explore outcomes 
after valve surgery due to RHD, conducted in a LMIC of the Fiji Islands, by one fly-in/fly-out 
cardiac surgical team, OHI. The specific aims were:   
1. To determine the short- and long-term mortality and morbidity outcomes of all 
patients who have undergone a mechanical VR surgery for RHD, performed by OHI in 
Fiji and identify independent predictors of these outcomes (Chapter Three); 
2. a. To identify what is known of HRQoL after a mechanical valve replacement 
surgery for adolescents and younger adults in developing countries by performing a 
literature review (Chapter Four) 
2.   b. To determine the pre-) and post-operative HRQoL outcomes of all surviving 
and contactable patients who underwent mechanical VR surgery for RHD, performed by 
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OHI in Fiji, and identify independent predictors of these outcomes (Chapter Five); and 
3. To determine anticoagulation (warfarin) adherence and predictors of non-
adherence for surviving, and contactable people who underwent mechanical VR surgery 
for RHD, performed by OHI in Fiji (Chapter Six). 
Thesis Structure 
The plan of this thesis was to investigate the short- and long-term health outcomes of 
mortality and morbidity; health-related quality of life (HRQoL); and self-reported adherence to, 
and knowledge of, warfarin therapy. A flow diagram showing how these link together is shown 
in Figure 1.  
Rationale, context and thesis structure is contained within Chapter One, 'Rational, context 
and thesis structure'. Concepts introduced in Chapter One are discussed in greater depth in 
Chapter Two, 'Introduction and background' which also situates the publication Chapters Three 
through Six. The surgical mortality and morbidity outcomes from this investigation are presented 
within Chapter Three. The literature specific to what was known about HRQoL amongst younger 
adults with mechanical valve prosthesis and the knowledge gaps, prior to commencement of the 
field-work phase of this study, is reported in-depth in Chapter Four within an integrative review. 
Addressing some of the HRQoL gap identified in Chapter Four, the HRQoL outcomes for this 
study are presented in Chapter Five. Findings arising from the investigation of warfarin 
knowledge, adherence and non-adherence phase which partially explain the mortality and 
morbidity findings in Chapter Three are contained within the publication in Chapter Six. Finally, 
Chapter Seven presents a summary of key findings, contextualises these to contemporaneous 
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research, discusses implications for practice, limitations and incorporates recommendations for 
future research.  
16 
 
 
  
 
   Figure 1: Thesis structure 
 
 
Chapter Four
Contains the integrative literature review identifying the gaps in 
knowledge relating to HRQoL of younger VR recipients and those in 
developing countries. 
Provides the foundation for Ch 5.
Chapter Three
Contains the research mortality and morbidity outcomes 
Amongst other findings, identifies stroke and bleeding as important 
causes of morbidity and mortality 
Chapter Seven
Summarises key research findings
Situates these to contemporaneous research and practice
Discusses implications for clinical practice
Details limitations and recommendations for future research.
Chapter Two
Detailed introduction and background for the research building on 
concepts introduced in Ch1. 
Provides context of conducting research in a LIMC and a summary 
of methods 
Chapter One
Rationale and context of the research
Broadly discusses overall research concepts 
Details thesis structure and research aims
Chapter Six
Contains the publication detailing the research findings on warfarin 
knowledge and adherence 
Findings provide some explanation for the outcomes detailed in Ch 3
Chapter Five
Contains the publication of the research HRQoL outcomes
Provides some possible explanations of findings which are discussed in 
greater detail in Ch 7
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Introduction to Chapter 
This chapter expands on the concepts introduced in Chapter One, and effectively is in 
four sections. The section is an overview of the etiological reasons for valvular heart disease that 
may lead to a requirement for VR surgery. RHD is explained from the perspective of global 
impact and disparities between HIC and LMIC, the historical context and the disease cascade 
that culminates in RHD including the stages where identification and antibiotic treatment would 
effectively halt disease progression and RHD-related mortality, morbidity and the impact on 
HRQoL. The second section explains the different valvular interventions, why mechanical VR 
surgery is commonly used for RHD, the VR surgical process and considerations, expands on 
antithrombotic therapy and details mechanical VR surgical mortality, morbidity and HRQoL. 
The third section hones in on patient specific self-management requirements including the 
implications of antithrombotic therapy in terms of medical surveillance requirements, 
recreational and pregnancy considerations. The final section provides the context of the research 
including methods for conducting research in a LIMC.  
Section One. Rheumatic Heart Disease 
Valvular heart disease.  
Valvular heart disease (VHD) has many causes and represents a significant, and 
increasing, global health burden (Iung & Vahanian, 2011; Moore, Chen, Mallow, & Rizzo, 
2016). Aetiology classification of VHD include: heritable-congenital; inflammatory-
immunogenic; degenerative; infiltrative, iatrogenic; neoplastic; endocardial and myocardial 
(Boudoulas, Borer, & Boudoulas, 2013; Iung et al., 2003; Otto & Bonow, 2012). Whilst a range 
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of treatment options and interventions exist for VHD, valve replacement (VR) surgery 
predominates (Iung et al., 2003).  
The aetiology leading to VR surgery differs markedly between LMICs and HICs 
(Carapetis, 2007; Carapetis, 2008; Carapetis, Currie, & Kaplan, 1999; Carapetis, Steer, 
Mulholland, & Weber, 2005; Samiei et al., 2014). In HICs, degenerative valvular changes over 
time predominate, and whilst prevalence generally increases with aging, there is a marked 
increase in valvular disease after the age of 65 years (Boudoulas et al., 2013; Iung & Vahanian, 
2011; Nkomo et al., 2006). Conversely, in LMICs, inflammatory-immunogenic aetiology, 
manifesting as RHD, is endemic and occurs most often in children, adolescents and younger 
adults (Abouzeid et al., 2017; Carapetis, 2007; Carapetis, 2008; Carapetis, Currie, et al., 1999; 
Carapetis et al., 2005).  
Rheumatic heart disease overview.  
A region is classified as RHD-endemic if RHD-related mortality for children aged four to 
nine years of age is greater than 0.15 deaths per 100,000 (Watkins et al., 2017). Currently, 
regions classified as endemic1 include the entire African continent, the Eastern Mediterranean, 
the Fiji Islands, India, the Maldives, Mauritius, Mongolia, Samoa, Saudi Arabia, Singapore, 
Solomon Islands, Timor-Leste, Tonga, Trinidad and Tobago, and Vanuatu (Watkins et al., 2017). 
Historical records indicate that acute rhematic fever (ARF) and RHD existed as early as 
the 1600s with a Frenchman, Guillaume de Baillou, credited for first describing (what we now 
call ARF) as a disease affecting the whole body as well as the joints (Vijayalakshmi, 2013). 
However, reliable population data did not exist until the early 1900s, when there was a re-
                                               
1 Mortality rate per 100,000, specific to each country listed was not detailed in the source publication. 
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emergence of ARF and RHD amongst industrialised countries (Carapetis, 2007; Kaplan, 1993) 
(Gordis, 1985; Raju & Turi, 2012). For example, in the United States of America (USA), ARF 
was endemic in the 1920s and again in the mid-1950s through the 1960s with a hospitalised 
prevalence of 15.6 per 100,000 in the Baltimore area during the latter period (Gordis, Lilienfeld, 
& Rodriguez, 1969; Vijayalakshmi, 2013). Also during this time, data from the New England 
region of the USA showed that almost 40% of cardiac admissions were RHD-related; whereas 
today, ARF and RHD account for less than 0.5% of primary discharge diagnoses in the USA 
(Padmavati, 2011; Raju & Turi, 2012). 
Despite the dramatic decline of ARF and RHD in HICs, these diseases continue to affect 
more than 33 million people globally are entirely preventable and disproportionally affect 
disadvantaged populations (Vos et al., 2016; Watkins et al., 2017). An estimated 80% of those 
affected by ARF and RHD live in LMICs with the remainder found amongst older, immigrant, or 
indigenous people within HICs (Carapetis et al., 2005; Celermajer, Chow, Marijon, Anstey, & 
Woo, 2012; Nulu, Bukhman, & Kwan, 2017; Rothenbuhler et al., 2014; Walsh et al., 2008; 
WHO, 2004; Zühlke et al., 2015).  
Importantly, RHD has a substantial impact on individuals’ lives at an estimated 1.6 
million YLD and more than 300,000 deaths annually (Celermajer et al., 2012; Nulu et al., 2017; 
Vos et al., 2016; Watkins et al., 2017; Zühlke et al., 2015). Globally, RHD has become the most 
common cause of acquired cardiovascular mortality and morbidity for children, adolescents, and 
younger adults (Nulu et al., 2017; Watkins et al., 2017; Zühlke et al., 2015). 
Disease process.  
The exact pathophysiology of RHD is yet to be precisely explained. It is known that the 
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development of RHD appears to be a result of a complex interplay between an individual’s 
susceptibility, environment (e.g., access to running water, sanitation, nutrition, and geographical 
location), bacterial virulence, and genetics (Gordis, 1985; Walsh et al., 2008). Additionally, 
factors related to ‘ethnic susceptibility’ are increasingly being investigated, with populations 
from Asia, sub-Saharan Africa and the Pacific Islands identified as particularly vulnerable 
(Kurahara et al., 2006; Mocumbi, 2015; Raju & Turi, 2012; Yiu, Tse, Mok, & Lau, 2011; 
Zühlke, Mirabel, & Marijon, 2013).  
Group-A streptococcal infections. The precursor to RHD, ARF, is an autoimmune 
response that develops as a reaction to group-A streptococcal (GAS) pharyngeal infections 
(Walsh et al., 2008; WHO, 2004). RHD is often described as a disease of poverty because the 
conditions that contribute to the spread of GAS infections, including overcrowding and reduced 
access to basic hygiene (e.g., running water and soap), are common to less-resourced 
communities and LMICs (Carapetis, Currie, et al., 1999; Hajar, 2016; McDonald et al., 2008; 
WHO, 2004). GAS infections are highly contagious; GAS bacteria are spread through direct 
person-to-person contact with saliva or nasal secretions (Centers for Disease Control and 
Prevention, 2016; Shulman et al., 2012). It has also been hypothesised that GAS virulence is 
amplified by rapid transmission across multiple hosts (Raju & Turi, 2012; Seckeler & Hoke, 
2011). 
Pharyngitis is a common ailment in childhood and is the leading cause of medical 
consultations for children and adolescents (Centers for Disease Control and Prevention, 2016; 
Shulman et al., 2012). However, in HICs only a small proportion (15%) of pharyngitis is caused 
by GAS (Centers for Disease Control and Prevention, 2016; Shulman et al., 2012). In contrast, in 
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ARF- and RHD-endemic regions, conservative estimates suggest that at least a third of 
pharyngitis cases are caused by GAS infections (Shaikh, Leonard, & Martin, 2010; 
Wannamaker, 1973). Unfortunately, there are no clear signs or symptoms that can distinguish a 
GAS pharyngeal infection from other bacterial, viral or non-infectious causes; definitive 
diagnosis can only be made from a throat swab, rapid antigen detection test (RADT) and/or 
culture (Centers for Disease Control and Prevention, 2016; Shulman et al., 2012). A positive 
RADT is highly specific; therefore, culture is only advised in circumstances in which RADT is 
negative and if the patient is a child or adolescent (Shulman et al., 2012). 
In HICs, antibiotic treatment of pharyngitis is not usually recommended unless the 
patient has a positive RADT (Shulman et al., 2012). Conversely, in endemic ARF and RHD 
regions, diagnosis and antibiotic treatment are critical given the poor potential outcomes of GAS 
pharyngitis when left untreated. However, access to the specialised laboratory testing facilities 
required for RADT are limited or non-existent in such regions (Gerber et al., 2009; Guidos, 
2011). This mean that a ‘treat all with antibiotics’ approach to pharyngitis is strongly 
recommended in countries with a high ARF and RHD burden, scant laboratory diagnostic 
services, and limited access to health workers (Carapetis & Currie, 1996; Irlam, Mayosi, Engel, 
& Gaziano, 2013; WHO, 1990). This is known as primary prevention. 
In the presence of GAS, primary prevention of ARF with appropriate antibiotic treatment 
is very effective. A full 10-day course of oral penicillin-V, amoxicillin, or a single intramuscular 
injection (IMI) of Benzathine Penicillin-G (BPG) within nine days of pharyngitis symptoms 
reduces ARF occurrence by between 70% (oral) and 80% (IMI) (Gordis et al., 1969; Robertson, 
Volmink, & Mayosi, 2005; Shulman et al., 2012). However, if the condition is left untreated, 
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around 3% of infected children will develop ARF within two to six weeks of the onset of GAS 
pharyngitis (Gordis, 1985). While these numbers may seem relatively minor, findings from a 
large-scale, longitudinal, epidemiological study based in the USA in the early 1960s (when RHD 
was endemic), indicated that the average child had one GAS infection by age five and at least 
three by age 13 (James , Badger , & Dingle 1960; Taranta et al., 1964). Importantly, the risk of 
ARF increases substantially (from 25% to 75%) after repeated occurrence of GAS pharyngitis 
(Taranta et al., 1964),(Denny, 1987; Feinstein et al., 1959). A meta-analysis evaluating the 
effectiveness of ARF primary prevention calculated an estimated 60% reduction in ARF would 
occur if GAS pharyngitis was treated appropriately (Lennon, Kerdemelidis, & Arroll, 2009). 
Acute rheumatic fever. ARF is classified as a non-suppurative GAS pharyngeal cascade 
during which rheumatogenic strains of streptococcus pyogenes produce large amounts of an ‘M 
protein’ and a hyaluronic acid capsule (Rao, 2006). Streptococcal antigens cross-react with 
human tissue and the patient’s own anti-streptococcal antibodies to initiate a reaction that causes 
inflammatory lesions in subcutaneous tissue, joints and the heart (Raju & Turi, 2012; Rao, 2006). 
The typical ARF patient exhibits effects across multiple body systems, including the immune 
system, brain, joints, subcutaneous tissues, and heart. As a result, symptoms may include fever, 
Sydenham’s chorea, localised and migratory arthritis, erythema marginatum and carditis 
(Carapetis, Brown, & Walsh, 2006; Raju & Turi, 2012; Zühlke et al., 2015). Of the various 
symptomatologies patients may experience when they have ARF, it is rheumatic carditis that 
results in permanent and/or cumulative damage to the valves and valvular structures of the heart 
(Otto & Bonow, 2012; Vijayalakshmi & Narasimhan, 2011; Walsh et al., 2008; WHO, 2004). 
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Once a patient has had ARF, secondary prevention is necessary to halt progression to 
RHD. Secondary prevention has been the core element in all RHD prevention programs since 
penicillin became available for non-military use in 1945 (Colquhoun, Carapetis, Kado, & Steer, 
2009; Nulu et al., 2017; WHO, 2000, 2004; World Heart Federation, 2007). Current American 
Heart Association (AHA) guidelines specific to RHD recommend administration of BPG IMI at 
three to four weekly intervals for 10 years or until the age of 21 (whichever represents the greater 
period of time) (Gerber et al., 2009). In the presence of RHD and/or after valvular intervention, 
this prophylaxis is to continue to age 40 (Gerber et al., 2009). Importantly, the focus is on 
individualised prophylaxis, because patients that continue to live in endemic regions may require 
lifelong prophylaxis to prevent repeat occurrences of ARF and to slow RHD lesion development 
(Gerber et al., 2009; Walsh et al., 2008; Wyber, Taubert, Marko, & Kaplan, 2013). Yet evidence 
from RHD-endemic regions suggests that often it is only the very symptomatic patient 
experiencing severe arthritic-type pain and/or heart failure that seeks medical care (Gapu et al., 
2015; Walsh et al., 2008). More commonly, previous occurrences of ARF and progression to 
RHD are only identified during a symptomatic presentation to hospital or during screening, such 
as those which occur at targeted schools, during research studies or incidentally at health clinics 
(e.g., antenatal checks) (Mocumbi, 2015; Sliwa et al., 2010; Steer, Kado, et al., 2009; 
Vijayalakshmi & Narasimhan, 2011; Zuhlke et al., 2015; Zühlke et al., 2015). 
The progression from ARF to RHD is not well understood and there is substantial 
variability by socio-economic region. For instance, the ongoing Global Rheumatic Heart Disease 
Registry (REMEDY) study (consisting of 14 countries and 25 hospitals) found that of the 
patients diagnosed with RHD (n = 3,343), less than one-fifth (n = 247; 22.3%) of patients from 
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low-income countries (LICs) had a history of ARF compared to 44% (n = 593) from LMICs, and 
59% (n = 500) from upper middle-income countries (UMICs) (Zühlke et al., 2015). For the 
Pacific Islands, a similar case to the reported LICs is likely; however, this is hard to confirm in 
the absence of rigorous data.  
Personal experience indicates a relative lack of ARF diagnoses. In two decades worth of 
in-depth conversations with RHD patients and families in Tonga, Fiji and Vanuatu, few people 
had any recollection of being unwell. A minority of parents or patients did recall some of the 
symptoms of ARF, such as aching joints, fever and fatigue, but these symptoms were considered 
a part of ‘growing up’, or as a consequence of ‘playing too hard’. Thus, treatment was not 
sought. It is hoped that screening and education programs begun recently in this area may help 
elucidate prevalence. 
The presentation of RHD. RHD is the term used to encompass the chronic cardiac 
valvular damage as sequelae to ARF (WHO, 2004; WHO, 2004). The permanent damage to the 
cardiac valve or valves and surrounding structures arising from rheumatic carditis includes 
scarring, thickening and/or contracting of valvular tissue, otherwise known as lesions (Bender, 
1992; WHF, 2007; WHO, 2004). Valvular stenosis occurs when lesion formation causes the 
valve leaflets to adhere to one another restricting forward blood flow (Bender, 1992). Valvular 
regurgitation develops when the lesions cause the valve leaflets to thicken and adhere to the 
walls of the heart, preventing closure and allowing blood to flow backwards (Bender, 1992). 
RHD primarily affects the mitral valve (Otto & Bonow, 2012; Walsh et al., 2008). Mitral 
regurgitation (MR) is the more common presentation in children and younger adults; mitral 
stenosis (MS) tends to appear later, in the third and fourth decades of life (Otto & Bonow, 2012; 
33 
 
WHF, 2007). However, the natural history and effects of RHD are increasingly understood to 
vary geographically. In the Northern Territory of Australia, 30% of Aboriginal and Torres Strait 
Islanders present with advanced MS between the ages of 10 and 19 years (Walsh et al., 2008). In 
LMICs—including India (Shrivastava & Tandon, 1991), Fiji Islands (Singh, Carapetis, 
Buadromo, Samberkar, & Steer, 2008), and Ethiopia (Tadele, Mekonnen, & Tefera, 2013)—
children are presenting with advanced MS at an average age of 10 years. RHD also affects the 
aortic valve and this may present concurrent with MS (Blackburn & Bookless, 2002; Otto & 
Bonow, 2012; Raju & Turi, 2012). RHD damage to the tricuspid (TV) and pulmonary valves 
(PV) is rare in isolation and is more likely to occur in advanced RHD. More than 90% of patients 
with rheumatic TV and/or PV will have concurrent severe mitral valve disease (Nulu et al., 2017; 
Raju & Turi, 2012; Sultan et al., 2010; WHO, 2004). 
Patterns of RHD progression vary significantly by region. For example, worsening of 
valvular regurgitation and/or stenosis to a symptomatic state is more rapid in people living in 
central sub-Saharan Africa and the Pacific Islands, occurring within months or years (Marijon, 
Mirabel, Celermajer, & Jouven, 2012; Mocumbi, 2015; Okello, Longenecker, Beaton, Kamya, & 
Lwabi, 2017; Raju & Turi, 2012; Singh et al., 2008; Zühlke et al., 2015; Zühlke et al., 2013). In 
contrast, patients in India and Western Europe more commonly require treatment and/or 
intervention 15 to 20 years after RHD diagnosis (Marijon et al., 2012; Okello et al., 2017; Otto & 
Bonow, 2012; Raju & Turi, 2012). The haemodynamic abnormalities of RHD lead to ventricular 
remodelling, dilatation and symptomatic heart failure (Walsh et al., 2008; Walsh, 2010). Timely 
VR surgery and lifelong medical surveillance is required to prevent RHD progression to valvular 
cardiomyopathy, end-stage heart failure and premature death (Nulu et al., 2017; Otto & Bonow, 
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2012; Zühlke et al., 2015). 
Rheumatic heart disease mortality.  
Severe RHD is fatal in the absence of surgical intervention; as previously noted, it is 
estimated to cause more than 300,000 deaths annually. Most of these deaths occur in younger 
adults (Celermajer et al., 2012; Nulu et al., 2017; Vos et al., 2016; Zühlke et al., 2015). Estimates 
from the REMEDY study identified Oceania, South Asia, and sub-Saharan Africa as having the 
highest age-standardised death rates; with India (119,100), China (72,600), and Pakistan (18,900) 
having the greatest numbers of RHD-related deaths (Watkins et al., 2017). In terms of highest 
age-standardised death rates, 13 countries were estimated to be greater than 10 per 100,000 of 
population:2 Central African Republic, Federated States of Micronesia, Fiji, India, Kiribati, 
Lesotho, Marshal Islands, Pakistan, Papua New Guinea, Solomon Islands, and Vanuatu (Watkins 
et al., 2017). 
There is a paucity of data detailing age at time of death, with only one study sourced for 
the West Pacific and Oceania region (Singh et al., 2008). This was conducted in the Fiji Islands 
and involved the analysis of autopsy data. While mortality data are best obtained from death 
certificates in rigorously monitored populations, this is rarely the case in LMICs. Thus, autopsy 
review is an alternate crude measure used (Singh et al., 2008). Singh et al. (2008) identified 38.1 
years as mean age of death (SD 17.8; range 4–72 years), with a quarter of deaths occurring in 
patients aged five to 24 years (n = 24). Heart failure was the most common cause of death 
(n = 75; 79%), including three young pregnant women (aged 26, 27 and 31 years) (Singh et al., 
2008). 
                                               
2 Age standardised death rates per 100,000, specific to each country listed was not detailed in the source publication 
other than as 'greater than 10 per 100,000'. 
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More recent data from three studies based in sub-Saharan Africa have provided further 
evidence of the impact of RHD on younger adults. A longitudinal follow-up of patients from a 
RHD registry in Ethiopia identified RHD deaths occurring at a rate of 125.3 per 1000 person 
years (95% CI: 67.4; 232.9) annualised to 12.5% occurring per year, with 22 years being the 
mean age at death (Günther, Asmera, & Parry). A retrospective chart review from a teaching 
hospital in Ethiopia found the mean age at death to be 25.9 years (SD 11.1 years), (Oli & 
Asmera, 2004) whereas, a prospective longitudinal follow-up in Uganda had a one-year mortality 
rate from diagnosis of 17.8% (n = 59), with 29.4 years being the mean age at death (Okello et al., 
2017). 
Rheumatic heart disease morbidity.  
In the absence of timely valvular intervention, RHD morbidities are severe. Atrial 
fibrillation (AF), thromboembolic stroke, infective endocarditis (IE) and heart failure are the 
most frequently occurring morbidities arising from RHD (Bender, 1992; Nulu et al., 2017; 
Okello et al., 2017; WHF, 2007; WHO, 2004). While approximately 10% of LMIC patients 
diagnosed with RHD have concomitant AF (Mirabel et al., 2015; Sliwa et al., 2010; Zühlke et 
al., 2015), the REMEDY study (n = 3,343) found the incidence of AF on initial RHD 
presentation to be double this, at 20.8% (mean age 28 years) (Zühlke et al., 2015). However, 
within the same study, a greater number of those diagnosed with RHD were on an antiarrhythmic 
(digoxin) and/or beta-blockers (34.7% and 39.3% respectively), suggestive of a higher presence 
of previous AF (Zühlke et al., 2015). Notably, in a smaller prospective study in Uganda 
(n = 449), with a median participant age of 30 years, 63.7% (n = 286) of patients without AF on 
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enrolment, proceeded to develop AF during the one-year follow-up from initial RHD diagnosis 
(Okello et al., 2017). 
Among the general HICs populations, the presence of AF increases the risk of stroke 
fivefold (Morady & Zipes, 2012). For patients with RHD, concomitant AF and/or the blood flow 
turbulence associated with rheumatic valvular abnormalities and/or debris thrown off from IE 
heightens the already high risk of thromboembolic stroke and embolic events (Morady & Zipes, 
2012; Otto & Bonow, 2012; Vijayalakshmi & Moorthy, 2011). Data on RHD-related stroke 
incidence, occurring within two years or less of initial RHD diagnosis, range from 2% (Okello et 
al., 2017) to 24.5% (Akdemir et al., 2002). RHD is a major contributing factor in the 
development of IE due to a combination of disturbed valvular blood flow and irregular 
endocardial surface (Karchmer, 2012; Vijayalakshmi & Moorthy, 2011). IE incidence from 
initial RHD diagnosis has been identified as ranging from 5.3% within the first year in an 
Ugandan sample (Okello et al., 2017) to 26% within the first 30 months in the Heart of Soweto 
study (Zühlke et al., 2015). 
The incidence of rheumatic heart failure is high in many LMICs, due in part to delayed 
diagnosis and rapidity of RHD progression (Mirabel et al., 2015; Zühlke et al., 2015). Of the 
3,296 patients enrolled in the REMEDY study, more than two-thirds (67.8%, n = 2,239) had 
heart failure and were on diuretic therapy (Zühlke et al., 2015). A smaller Ugandan investigation 
(n = 331) demonstrated the rapidity of RHD progression to heart failure even in the presence of 
medical surveillance, with over a third (n = 116) of patients developing decompensated heart 
failure during the one-year follow-up (Okello et al., 2017). While end-stage heart failure and 
death are the primary end-points of RHD, it has been well established that early diagnosis, strict 
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secondary prophylaxis adherence and access to suitably timed valvular interventions 
significantly reduces morbidity and mortality (Mirabel et al., 2015; Walsh et al., 2008; Wyber et 
al., 2014; Wyber et al., 2013).  
Rheumatic heart disease HRQoL.  
Over the past 20 years, HRQoL has become an increasingly important outcome, 
alongside the more traditional mortality and morbidity outcomes (Bowling, 2005; Karimi & 
Brazier, 2016). While quality of life (QoL) and HRQoL continue to be used interchangeably in 
the literature, measures of HRQoL are specifically aimed at empirically assessing the effect of a 
disease state or health intervention on an individual’s QoL (Bowling, 2005; Karimi & Brazier, 
2016). In 2010, the AHA included HRQoL outcomes as a strategic treatment impact goal for the 
national cardiovascular health promotion and disease reduction strategy through to 2020 (Lloyd-
Jones et al., 2010). 
Limited resources have substantial effects on health care in LMICs (Carapetis et al., 
2005; de Dassel, Ralph, & Carapetis, 2015; Roberts et al., 2014; Rothenbuhler et al., 2014). The 
lack of available resources reduces the ability to collect, manage and analyse data, such as that 
required for RHD registries and investigation of outcomes including HRQoL. Consequently, 
there is a lack of published data on the impact of RHD on HRQoL in LMICs and/or specific to 
younger adults. Nonetheless, findings from the REMEDY study (n = 3,343) clearly identified 
areas that suggest RHD is likely to profoundly impact HRQoL (Zühlke et al., 2015). Of those 
enrolled, most were young (median age 28 years), yet were largely unemployed (75.3%); 
females were over-represented at 66% (with around 88% of those in LMICs being of child-
bearing age); 40% had congestive heart failure and at least 20% had AF (Zühlke et al., 2015). 
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The latter two clinical syndromes are well-recognised as impairing HRQoL in HICs; however, 
these conditions are predominately seen in older age groups than the rheumatic populations of 
LMICs (Coelho et al., 2005; Dorian et al., 2000; Hagens et al., 2004; Heo, Lennie, Okoli, & 
Moser, 2009; Moser et al., 2013; Ramos, Prata, Gonçalves, & Coelho, 2014). Importantly, the 
younger age and formative life stage of rheumatic patients are likely to be contributory factors to 
impaired HRQoL; older patients with heart failure were found to report better HRQoL than 
younger patients with similar conditions (Moser et al., 2013). 
Section Two. Valve Surgery 
Role of surgery.  
Given the damaging effects of RHD on heart valves and the mortality, morbidity and 
reductions in HRQoL, the role of surgery in reducing these effects is crucial. Many patients 
affected by RHD in LMICs require valve surgery or face premature death (Wyber et al., 2014; 
Zühlke et al., 2015). This was clearly illustrated in the Heart of Soweto study, in which 22% of 
344 newly diagnosed cases of RHD at one urban centre required VR or repair within 30 months 
of diagnosis (Sliwa et al., 2010). However, access to VR is limited in LMICs. In the REMEDY 
study (n = 3,343) (Zühlke et al., 2015) only 26.7% of patients in LMICs received rheumatic 
valvular interventions, which was less than half of those living in UMICs (58.4%, n = 504) 
(Zühlke et al., 2015)3. 
In the absence of timely surgery, patients who become symptomatic have a significantly 
shortened lifespan (Carapetis et al., 2006; Wyber et al., 2014; Zühlke et al., 2015). Current 
international valvular management guidelines and RHD consensus documents recommend 
                                               
3 'n' data from Table 2 in referenced paper; however, the percentages were manually recalculated as some of the 
percentages reported in the paper were incorrect when cross-checked. 
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surgery occur before significant irreversible damage is sustained to the anatomical structure of 
the heart sufficient to cause reduced left ventricular function (LVF) (Baumgartner et al., 2017; 
Nishimura et al., 2017; Walsh et al., 2008). With increasingly impaired LVF, heart failure 
worsens and death occurs in up to 25% of RHD patients each year; therefore, access to surgery is 
a literal life or death situation (Carapetis et al., 2006; WHO, 2004). 
 
Valve repair versus replacement.  
Valvular repair is recommended as the tertiary treatment of choice for RHD in HICs 
notwithstanding a subset of criteria in which balloon valvotomy, closed or open surgical 
valvotomy and mechanical valve implantation is recommended in the first instance (Bakir, Onan, 
Onan, Gul, & Uslu, 2013a; Bakir, Onan, Onan, Gul, & Uslu, 2013b; Bonow et al., 2008; 
Choudhary et al., 2001; Finucane & Wilson, 2013; Otto & Bonow, 2012; Russell et al., 2014; 
Vahanian et al., 2012; Walsh et al., 2008). Repair, or valvotomy, reduces the requirement for 
long-term antithrombotic therapy, minimises thromboembolic risks of mechanical prosthesis and 
associated lifestyle implications, reduces the risk of prosthetic valve-related endocarditis and 
decreases the frequency of medical surveillance, which is the most important benefit for 
adolescents and young adults (Bakir et al., 2013a; Bonow et al., 2008; Mellwig, van Buuren, 
Gohlke-Baerwolf, & Bjornstad, 2008; Otto & Bonow, 2012; Walsh et al., 2008; Zacek et al., 
2016). However, repairing RHD damaged valves is technically difficult, time consuming and 
requires a highly skilled multidisciplinary team to execute the procedure successfully, and 
ultimately is dependent on the level of damage (Bakir et al., 2013a; Finucane & Wilson, 2013; 
Mick, Keshavamurthy, & Gillinov, 2015; Otto & Bonow, 2012). 
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Even with the highest levels of expertise, the RHD inflammatory processes cause 
unpredictable levels of fibrosis, calcification, adhesions and/or fusion across the valvular 
structures, including leaflets, chordae, papillary muscles, commissures and annulus. 
Consequently, the end-point of repair attempts often morph into a VR after intra-operative echo 
(Bakir et al., 2013b; Bonow et al., 2008; Otto & Bonow, 2012). Consequently, mechanical VR 
surgery is the most common, pragmatic, RHD tertiary treatment in LMICs, including Pacific 
Island countries (Akhtar et al., 2011; Davis, Wainer, O'Keefe, & Nand, 2011; Tefuarani et al., 
2007; Zühlke et al., 2015). 
Mechanical valve replacement surgery.  
Open heart procedures, including VR surgery, involve a continuum of care from 
diagnosis through preoperative preparation and education, surgery, ICU, through to the ward, 
discharge, recovery, and rehabilitation (Raper, 2009). In HICs, such as Australia, USA and the 
United Kingdom (UK), VR patients receive preoperative counselling and education on what to 
expect during and after surgery, along with appointments for preoperative investigations. This 
may take place in the surgeon’s rooms or in a pre-admission clinic. Printed information and 
electronic resources are provided, including information across the spectrum of surgical 
preparation such as what occurs during surgery, and what to expect in ICU, during postoperative 
and post-discharge recovery. These may include surgeon-specific and/or generic brochures from 
cardiac prosthesis companies, cardiac centres (such as the Mayo Clinic) and national heart 
foundations (such as the AHA) (American Heart Association, 2017; Edwards Lifesciences, 2017; 
National Heart Foundation of Australia, 2015). Psychosocial, physical function, dietary and 
lifestyle advice, such as resumption of driving and sexual activity, are addressed (Baumgartner et 
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al., 2017; Heart Foundation, 2015). Recovery trajectory and milestones are discussed 
preoperatively and again in greater detail once the patient is closer to discharge. For mechanical 
VR patients, this also includes IE precautions, warfarin education, and antithrombotic 
management (Baumgartner et al., 2017; Butchart et al., 2005; Heart Foundation, 2015; Oterhals, 
Fridlund, Nordrehaug, Haaverstad, & Norekval, 2013). Post-discharge cardiac rehabilitation, 
either as in- or out-patient is recommended (Butchart et al., 2005; Heart Foundation, 2015; 
Oterhals et al., 2013). 
Operative process. Surgical replacement of rheumatic valves with mechanical prostheses 
is a major undertaking (Otto & Bonow, 2012; Raper, 2009). Surgery takes three to six hours and 
is performed under general anaesthetic, with access through a sternal split and the use of 
cardiopulmonary bypass machine (Moser & Riegel, 2007; National Heart Foundation of 
Australia, 2007). Postoperatively, the intubated and unconscious patient is transferred to the ICU 
where they are mechanically ventilated until hemodynamically stable (Moser & Riegel, 2007). 
Twenty-four to 48 hours later, patients are transferred to a step-down unit or ward where cardiac 
monitoring, physiotherapy and medication adjustments (commonly diuretics, plus or minus beta-
blockers and antiarrhythmic varying with cardiac rhythm and rate) continue during recovery 
(Baumgartner et al., 2017; Butchart et al., 2005; Moser & Riegel, 2007; Nishimura et al., 2014; 
Raper, 2009). 
Anti-thrombotic management after mechanical VR.  
Patients with mechanical valves require lifelong antithrombotic management and 
warfarin is the only anticoagulation medication proven efficacious (Baumgartner et al., 2017; 
Butchart et al., 2005; Nishimura et al., 2017). Warfarin has a very narrow therapeutic window 
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(the half-life of warfarin is 36 to 48 hours) and a highly variable, intra-patient, anticoagulation 
effect, necessitating close medical surveillance of INR testing and dosage titration (Ansell et al., 
2004; Butchart et al., 2005; Leiria et al., 2011; Nishimura et al., 2017; Roudaut, Serri, & Lafitte, 
2007). Recent consensus (2017) between the AHA/American College of Cardiology (ACC) and 
European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery 
(EACTS) endorsed guidelines to redefine INR goals to be a target number instead of the 
traditional INR range; however, this remains uncommon in practice (Baumgartner et al., 2017; 
Nishimura et al., 2017). While usual in-hospital recovery varies from six to nine days, patients 
remain in hospital until their INR is therapeutic and warfarin dose is stable (Akins et al., 2008; 
Ansell et al., 2004; Geissler, Schlensak, Sudkamp, & Beyersdorf, 2009; Iung & Rodés-Cabau, 
2014; Nishimura et al., 2017; Walsh et al., 2008). 
Anti-thrombotic bridging therapy. Consensus guidelines recommend continuous 
intravenous unfractionated heparin (UFH) as bridging antithrombotic therapy for all mechanical 
valves until the INR is therapeutic (Baumgartner et al., 2017; Iung & Rodés-Cabau, 2014; 
Nishimura et al., 2017). Subcutaneous use of low molecular weight heparin (LMWH) is 
discussed in all guidelines and deemed an effective and stable alternative bridging measure; 
however, no recommendations have been made for its use, due to these drugs being ‘off label’ in 
the USA and Europe (Baumgartner et al., 2017; Iung & Rodés-Cabau, 2014; Nishimura et al., 
2014; Nishimura et al., 2017). Current ESC/EACTS guidelines do not recommend concurrent, 
antiplatelet therapy (low-dose aspirin) as a routine adjunct to warfarin, but suggest it be used on 
an individual patient risk–benefit basis, along with consideration of valve position, comorbidities 
and individual surgeon preference (Iung & Rodés-Cabau, 2014; Nishimura et al., 2014), (Kulik 
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et al., 2006). Conversely, AHA/ACC guidelines recommend lifelong low-dose aspirin concurrent 
with warfarin for all patients with mechanical valves (Nishimura et al., 2017). 
Risks associated with anti-thrombotic management. Warfarin causes major bleeding in 
1–2% of patients treated, and intracranial bleeding at a rate of 0.01–0.05% during each year of 
therapy (Gallus, Baker, Chong, Ockelford, & Street, 2000). The highest risk time for patients on 
warfarin is in the first three to six months from commencement of therapy (Gallus et al., 2000; 
Kulik et al., 2006; Leiria et al., 2011; Lip & Douketis, 2017; Waterman et al., 2004). This is 
further complicated by the fact that patients who are initially commenced on warfarin post-VR 
surgery have an increased sensitivity to warfarin, estimated to be between 30% and 50% greater, 
so that less warfarin is required to reach the target INR (Ageno & Turpie, 1999; Kulik et al., 
2006; Meijer, Kim, & Schulman, 2010). This increased sensitivity slowly plateaus over time, 
stabilising by around 12-weeks postoperatively (Ageno & Turpie, 1999; Kulik et al., 2006; 
Meijer et al., 2010). Consequently, patients are advised to have weekly INRs at least until the six 
week follow-up visit with the surgeon (Ageno & Turpie, 1999; Kulik et al., 2006; Meijer et al., 
2010). 
Thromboembolism risk after VR surgery is multifactorial and there are causes other than 
a sub-therapeutic anticoagulation state (Butchart et al., 2005). These may range from thrombus 
or vegetation, due to abnormal flow created by the prosthesis, to emboli developing as a 
consequence of low cardiac output in patients who may have structural valve deterioration after 
surgery (Butchart et al., 2005). 
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Post-discharge considerations.  
Other postoperative physiologic concerns include the risk of haemolytic anaemia arising 
from prosthetic heart valve damage to the red blood cells, valve thrombus, noise disturbance 
from the sound of the prosthesis, and the need for endocarditis prophylaxis (Baumgartner et al., 
2017; Butchart et al., 2005; Geissler et al., 2009; Koertke et al., 2003; Nishimura et al., 2017). 
The latter is vital in the first three to six months after surgery in which there is an increased risk 
of the development of prosthetic valve endocarditis (Baumgartner et al., 2017; Butchart et al., 
2005; Nishimura et al., 2017). Further, all VR patients need closely supervised IE antibiotic 
prophylaxis before undergoing any dental, endoscopic or surgical procedure (Bonow et al., 1998; 
Butchart et al., 2005; Nishimura et al., 2017). 
Postoperative follow-up with the cardiologist is recommended at four weeks and the 
surgeon at six weeks to assess recovery (Baumgartner et al., 2017; Butchart et al., 2005). 
Transthoracic echocardiography (TTE) is recommended at four weeks and one year 
postoperatively, then annually for life (Baumgartner et al., 2017). Lifelong cardiology 
surveillance is required to evaluate LVF, identify early deterioration of prosthetic valve function 
or disease progression of native valves (Baumgartner et al., 2017). During the surgical check-up, 
results from routine follow-up investigations (such blood tests, the TTE and chest X-ray) are 
examined (Butchart et al., 2005). The patient is also assessed for symptomatic status and 
physical functioning, and their surgical wounds are inspected for healing (Butchart et al., 2005). 
Apart from the assessment of physiologic status, the follow-up appointment with the cardiac 
surgeon provides an opportunity for patients to obtain reassurance about their recovery trajectory 
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and to ask questions about any recovery concerns they may have, including advice about 
returning to work (Moser & Riegel, 2007). 
Mechanical VR postoperative restrictions.  
Patients are advised to avoid all contact sports, due in part to the risk of blunt force 
trauma to the chest area potentially affecting the valve, and the risk of haemorrhage secondary to 
their anticoagulation therapy (Bonow, Cheitlin, Crawford, & Douglas, 2005). Lifelong warfarin 
therapy for VR patients poses additional risks for women of child-bearing age. Preoperative 
counselling on the extreme risk to mother and foetus when attempting pregnancy concurrent with 
antithrombotic management, and a requirement for long-term contraception such as 
contraceptive implants, or tubal ligation, must occur in order for the patient to make an informed 
decision to have a mechanical valve (Bonow et al., 1998; Elkayam, Goland, Pieper, & Silverside, 
2016a). 
Mechanical VR surgery mortality.  
VR surgery usually leads to an improvement in symptoms and prognosis but even in 
optimal circumstances, life expectancy after surgery is recognised to be lower than that of the 
general population (Bonow, Nishimura, Thompson, & Udelson, 2015; Choudhary, Talwar, & 
Airan, 2016; Mellwig et al., 2008; Pelliccia et al., 2005). 
The mortality after major VR surgery is low in the short term. In HICs, in-hospital 
mortality rates range from 2% to 5% (Cowles, 2008) and at three months after discharge this 
increases to between 5% (Chocron et al., 1996) and 13.1% (Goldsmith, Lip, & Patel, 2001b). 
One year after surgery, mortality rates vary considerably from 2.5% (Baberg et al., 2004) to 
20.9% (Maliwa et al., 2003), and at 10 years from 16% (Ruel et al., 2005) to 34% (Cowles, 
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2008). There are many factors known to influence mortality and survival including age, the 
presence of comorbid conditions, type of valve prosthesis inserted and the position of the valve 
within the heart, and the severity of the underlying disease (Akins et al., 2008; Baumgartner et 
al., 2017; Iung & Rodés-Cabau, 2014; Nishimura et al., 2017). For example, in-hospital mortality 
rates for aortic VR range from 4.3% to 6.4% compared to 10% for mitral VR patients 
(Allareddy, Ward, Ely, & Levett, 2007; Astor, Kaczmarek, Hefflin, & Daley, 2000). 
On commencement of the research contained in this thesis, there was a paucity of 
mortality data specific to RHD VR patients. A Canadian study (n = 269) of middle-aged (mean 
age 56 years, SD 0.7 years) RHD VR patients reported an in-hospital mortality rate of 4% and 
10-year mortality rate of 27% (Yau, El-Ghoneimi, Armstrong, Ivanov, & David, 2000). Eight 
year mortality rates for young (mean age 14.4 years, SD 2.9 years) RHD VR patients (n = 52) in 
a LMIC, with in-country surgical capability, were 14% (Travancas et al., 2009). Thus, the 
longer-term mortality rates for RDH VR were 14% to 27%, which approximates to the non-RHD 
VR 10-year mortality range of 16% (Ruel et al., 2005) to 34% (Cowles, 2008) detailed above. 
Factors such as socio-economic status, ethnicity, age, and health-service access have 
previously been associated with mortality risk in cardiac surgical populations (Carapetis, Powers, 
et al., 1999; Lehman, Baker, Aylward, Knight, & Chew, 2009; Russell et al., 2015; Sliwa et al., 
2010; Thomson & Gray, 2013). The influence of these factors among RHD VR patients is 
exemplified in a study (n = 47) of indigenous RHD VR patients (median age 40 years, range four 
to 76 years) living remotely in the Cape York Peninsula and Torres Strait Islands, Australia 
(McLean, Waters, Spencer, & Hadfield, 2007). These indigenous patients had a 10-year 
mortality rate of 48%, which contrasts starkly with the RHD VR patients from the Brazilian and 
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Canadian studies (McLean et al., 2007). Ease of access to medical services, considering the high 
level of medical surveillance and lifelong follow-up requirements of mechanical VR patients, 
would seem a critical factor for improved outcomes, and accordingly outcomes of RHD VR 
patients living in LMICs warrant further investigation (McLean et al., 2007; Walsh et al., 2008; 
Wyber et al., 2014). 
Mechanical VR surgery morbidity.  
Given the complexity of the RHD VR surgery and lifelong antithrombotic management 
requirements, morbidity is an important issue. In 2008, consensus guidelines covering all types 
of cardiac valvular interventions were released by the Councils of the American Association for 
Thoracic Surgery, the Society of Thoracic Surgeons, and the European Association for 
Cardiothoracic Surgery (Akins et al., 2008). Standardised reporting is necessary as it enables the 
comparison of outcomes. Reportable outcomes include structural valve deterioration; non-
structural dysfunction; valve thrombosis; embolism resulting in neurologic or non-cerebral 
embolic events; bleeding events; IE; and operative reintervention (Akins et al., 2008). In-hospital 
morbidity complications following VR surgery are common with over a third of patients 
(35.2%–36.4%) in HICs experiencing at least one complication (Allareddy et al., 2007). Data 
from the Nationwide Inpatient Sample database of United States hospitals 2002–2003 
(n = 16,516) identified that of these complications, half were cardiac-related and a quarter were 
bleeding events alone (Allareddy et al., 2007). 
Similar to VR mortality outcomes, morbidity rates after VR surgery are variable, with 
some studies reporting higher morbidity at six months postoperatively than other studies report at 
one year. For example, the morbidity rates for stroke and/or trans-ischemic events range from 
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13.4% at six months (Baberg et al., 2004) to 7.1% at one year (Rimington, Weinman, & 
Chambers, 2009), and bleeding events range from 15.5% at six months (Baberg et al., 2004) to 
12% at one year (Rimington et al., 2009). Among RHD patients in HICs, there is evidence to 
suggest that surgical VR-related morbidity continues to increase over time (Yau et al., 2000). 
Yau et al. (2000) investigated longer-term morbidity after RHD mitral VR surgery in an older 
Canadian population (mean age 54 years, SD 14 years) and identified that embolic events, IE and 
reoperation, occurred in 10% of patients by five years, but by 10 years, this had quadrupled to 
40% (Yau et al., 2000). 
There is also some evidence suggesting that younger age and socio-economic factors may 
contribute to higher morbidity. Morbidity outcomes from Italy (The World Bank, 2016) focused 
on women (mean age 31.4 years, SD 6.4 years) undergoing rheumatic mitral VR surgery, 
identified embolic events and reoperation to be 5.5% at five years and 9.7% by 10 years (De 
Santo et al., 2005). However, younger Brazilian patients (mean age 14 years, SD 2.9 years) 
having had aortic or mitral VR surgery appeared to fare less well with a reoperation incidence of 
13% and 56% at four and eight years (Travancas et al., 2009). When reoperation morbidity was 
combined with bleeding events and embolism events, the morbidity incidence rates of the 
Brazilian patients, for the same time periods, increased to 25% and 66% respectively (Travancas 
et al., 2009). 
The available evidence, allowing for study methodology variations, shows that younger 
RHD VR patients in a LMIC, such as Brazil, will, despite in-country specialised cardiothoracic 
services, have poorer long-term morbidity than older (although still relatively young) RHD VR 
patients in HICs, such as Canada and Italy. RHD VR patients in countries with an absence of in-
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situ capability to reoperate, or to readily access specialised cardiac surgical services could be 
expected to have poorer mortality and morbidity outcomes.  
Nonetheless, it is important to note that RHD VR surgery, for the most part, decreases 
RHD mortality and morbidity and aids in symptom reduction (Otto & Bonow, 2012; Rao, 2011). 
The requirement for lifelong self-management in a LMIC, particularly antithrombotic 
management, may profoundly influence mortality and morbidity outcomes. Apart from 
antithrombotic management, RHD VR self-management encompasses cardiac rhythm and rate 
control; IE and RHD precautions and prophylaxis; vigilance and awareness regarding dietary and 
medication interactions, maintenance of regular healthcare appointments and daily medication 
regimes; and knowledge of pregnancy and sporting restrictions (Baumgartner et al., 2017; 
Bonow et al., 2015; Butchart et al., 2005; Nishimura et al., 2017; Rao, 2011). 
Mechanical valve-related quality of life.  
The bulk of the literature related to the postoperative outcomes of VR for RHD is focused 
on mortality and morbidity regardless of context. However, as detailed earlier, in this chapter, 
HRQoL has evolved to become an important outcome measure. The interest in HRQoL 
outcomes over the past decade has been stimulated in part by medical success in prolonging life 
and with the associated realization that patients want to be able to their lives fully; not just 
simply survive (Aboud, Breuer, Bossert, & Gummert, 2009; McSweeny & Creer, 1995). Whilst 
detail on surgical mortality and morbidity rates is important to patients, understanding what 
benefits a surgical intervention may offer in terms of their HRQoL has become increasingly 
central to preoperative education and informed consent (Bingener, Sloan, & Boughey, 2014; 
Morris et al., 2006).  
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In general, HRQoL instruments are multi-dimensional and incorporate a variety of 
aspects or domains that are collectively considered to reflect the persons overall quality of life 
and the effect that their current health status may have (Bowling, 2005; McDowell, 2006). 
Domains covered vary between HRQOL instruments depending on their theoretical basis, but 
important domains include functional ability; current health perception encompassing physical, 
mental and emotional health; social functioning and interaction; and, subjective well-being. 
As detailed in Chapter One, Thesis Structure, the results pertaining to Aim Two a) ' To 
identify what is known of HRQoL after a mechanical valve replacement surgery for adolescents 
and younger adults in developing countries by performing a literature review ', are contained 
within Chapter Four, in the form of a focused publication, 'Health-related Quality of Life of 
Patients after Mechanical Valve Replacement Surgery: An Integrative Review'.   However 
included below are some aspects that were outside the scope of the publication.  
Overall HRQoL substantially improves following VR surgery for the majority of patients 
although small numbers have been found to continue to experience significant HRQoL 
impairment in specific domains, most commonly physical and emotional functioning (Baberg et 
al., 2004; Chocron et al., 1996; Koertke et al., 2003; Phillips & Lansky, 1992; Taillefer, Dupuis, 
Hardy, & LeMay, 2005). The passage of time since surgery appears to exert a substantial 
influence on HRQoL. Zhao et al., (2007) confirmed earlier findings by Phillips and Lansky 
(1992) that found HRQoL measured at one month postoperatively was worse than the 
preoperative assessment, but then improved to at least preoperative levels by three months. From 
three months, HRQoL improvement continued with most patients matching, or exceeding, 
population normative values from six to 12 months onwards as well as showing substantial gains 
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to their preoperative HRQoL scores (Phillips & Lansky, 1992; Zhao et al., 2007). The 
improvement in HRQoL appears to remain stable over the longer term with Perchinsky et al., 
(1998) noting that HRQoL, measured at five years postoperatively, was equivalent to that of age-
matched population norms. However, despite this sustained improvement over time, there was 
some variability in HRQoL observed by sub-groups.  
Older age was associated with greater HRQoL impairment particularly when measured 
during the recovery phase of surgery. An overall lack of improvement in HRQoL (Goldsmith, 
Lip, & Patel, 2001a) and impairment in the domain of physical functioning was found to be 
associated with older age (Phillips & Lansky, 1992). Older age was also an independent 
predictor for impairment in the domains of energy, sleep and social isolation (Chocron et al., 
1996). However, being older also appeared to provide some protective benefits over time, with 
Rimington et al.,(2009) identifying older age an independent predictor of significant 
improvement in composite mental status at one year postoperatively.  
 Results were inconsistent on the influence of gender on HRQOL. Goldsmith et al., 
(2001b) were the only authors to identify female gender as an independent predictor of less 
improvement in HRQOL at three months postoperatively. The small sample size (n=61) with a 
total of 34 females in the study and the fact that no other studies identified this as a predictor 
indicates that there may be other factors at play. There was also a propensity for female patients 
to show less improvement in physical functioning aspects of HRQoL with four studies finding 
impairment in these domains for women out to two years postoperatively  (Aboud et al., 2009; 
Chocron et al., 1996; Phillips & Lansky, 1992; Rimington et al., 2009). In contrast, one study 
(Taillefer et al., 2005) using similar populations in relation to age, gender, valve type and the 
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instrumentation, found that female patients performed substantially better than males, in domains 
relating to leisure, affectivity and social functioning.  
A strong association was found between worse (III and IV) NYHA heart function class 
and continuing HRQOL impairment postoperatively, particularly for the domains of 
energy/vitality, physical function, coping capacity and emotional status (Baberg et al., 2004; 
Chocron et al., 1996; Goldsmith et al., 2001b; Myken, Larsson, Larsson, Berggren, & Caidahl, 
1995; Phillips & Lansky, 1992). Only one study (Notzold et al., 2001) did not find any 
correlation between HRQOL and NYHA functional class, possibly due to the majority of 
patients in their study having a better functional class (I and II).  
The presence of concomitant comorbidities was identified as an independent predictor of 
HRQOL impairment, with the presence of  one or more comorbid diseases increasing the odds of 
a  patient having impairment in the domain of emotional reaction by up to two and a half times  
(Chocron et al., 1996). The most important comorbidities were diabetes mellitus, hypertension 
and morbid obesity.  Diabetes mellitus was found to be an independent predictor for impaired 
postoperative physical component scores (Baberg et al., 2004),  with hypertension and morbid 
obesity significantly correlated with poorer physical function scores (Phillips & Lansky, 1992). 
The effect of complications such as bleeding, wound infection, and transischemic events, 
on postop HRQOL is inconsistent with two study’s reporting significant impacts on various 
domains (Baberg et al., 2004; Myken et al., 1995) and two others finding HRQOL unaffected  
(Chocron et al., 1996; Maliwa et al., 2003). Complications were an independent predictor of 
patients unlikely to experience improvement in the physical and mental component scores 
component scores at six months postoperatively (Baberg et al., 2004),  and Myken et al.,(1995) 
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associated complications with poorer scores in the coping capacity domain at six years 
postoperatively. In contrast, two other studies (Chocron et al., 1996; Maliwa et al., 2003) 
conducting HRQoL measures at three months and 30 years postoperatively, respectively, could 
not find any difference in HRQoL due to complications.  
Section Three. Self-management 
Self-management, also known as self-care, has been defined as the strategies individuals 
enact to stay or become healthy (e.g., nutritious diet and exercise), manage illness (e.g., lifestyle 
changes, medications, and symptom control), and optimise life with a medical condition (e.g., 
modification of sport or leisure activities and adapting to losses caused by illness) (Audulv, 
Asplund, & Norbergh, 2011; de Meneses et al., 2015). It is plausible that the self-care 
requirements associated with a mechanical VR will profoundly affect the lives of younger adults 
regardless of their socio-economic status. 
As previously mentioned, RHD VR surgery offers extended longevity and symptom 
reduction but this comes at a cost: the need for life-long health self-management. Like any 
person managing a chronic health condition, some patients will find the above trade-off 
acceptable, but others will struggle with varying levels of acceptance and adherence (Al-Ganmi, 
Perry, Gholizadeh, & Alotaibi, 2016; Bycroft & Boyd, 2012). While RHD VR may alleviate the 
symptoms associated with a stenotic and/or incompetent valve, LV impairment may not be 
reversible. Consequently, many patients continue to require diuretics, beta-blockers, 
antiarrhythmic and other medications with antithrombotic management further increasing 
existing health self-management needs (Geissler et al., 2009; Walsh et al., 2008).  
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Patient considerations in antithrombotic therapy management.  
Antithrombotic management refers to all facets related to maintaining therapeutic INR, 
including medical surveillance, regular INRs, dose titration, dietary vigilance and perhaps most 
important of all, ongoing patient education. As mentioned in Chapter One, and throughout this 
chapter, warfarin is the only anticoagulation drug that has proven efficacious for people with 
mechanical valve prosthesis (Butchart et al., 2005; Iung & Rodés-Cabau, 2014; Kulik et al., 
2006; Nishimura et al., 2017). While warfarin is highly effective, it has a very narrow therapeutic 
window and a highly variable, intra-patient, anticoagulation effect, necessitating INR testing 
along with dosage titration (Ansell et al., 2004; Butchart et al., 2005; Leiria et al., 2011; 
Nishimura et al., 2017; Roudaut et al., 2007). INR variability is the strongest influence of 
adverse thromboembolic events and all-cause mortality (Butchart et al., 2005; Butchart et al., 
2002; Kulik et al., 2006; Lip & Douketis, 2017). However, a meta-analysis of anticoagulation 
studies indicated that patients on warfarin are outside the therapeutic zone at least a third of the 
time, with individual studies showing this can range from 57% to 72% (Lane & Lip, 2007; Oake, 
Fergusson, Forster, & van Walraven, 2007; van Walraven, Jennings, Oake, Fergusson, & Forster, 
2006; van Walraven, Oake, Wells, & Forster, 2007).  
Patient knowledge and understanding of the effect of warfarin, its contraindications and 
vast array of interactions, and symptoms that need to be reported to their doctor, are persistent 
themes in studies investigating warfarin adherence (Ababneh, Al-Azzam, Alzoubi, & Rababa’h, 
2016; Chenot et al., 2014; Hu, Chow, Dao, Errett, & Keith, 2006; Ingelgard et al., 2006). Other 
barriers to warfarin and other medication adherence includes the time required for clinic or GP 
attendance, necessitating time off work or school, the monotony of needing to take medication at 
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a similar time each day, dietary restrictions, and an absence of internalising the risks of 
discontinuation, or non-adherence (Altiok, Yilmaz, & Rencüsoğullari, 2015; Atrial Fibrillation 
Association and AntiCoagulation Europe (UK), 2012; Cruess et al., 2010; Fang et al., 2010; 
Gebler-Hughes, Kemp, & Bond, 2014; Hu et al., 2006; Ingelgard et al., 2006; Mair et al., 2012). 
Importantly, there is also evidence that in-hospital education has little effect on patient 
knowledge but rather it is ongoing, continuous and specific information at specialised out-patient 
clinics that promotes the greatest understanding and adherence (Ababneh et al., 2016; Hu et al., 
2006), (Chenot et al., 2014). 
Dietary interactions and restrictions associated with anti-thrombotic therapy. Warfarin 
is a vitamin K antagonist, metabolised by the liver and its potentiation is affected by multiple 
interactions. Green leafy vegetables are the highest source of dietary vitamin K but other 
common sources include liver and other organ meats, soya products, garlic, and high intake of 
green tea (Ansell et al., 2004; Kampouraki & Kamali, 2017). Alcohol interaction varies with the 
degree of alcohol intake. Chronic alcohol use activates a hormone that increases warfarin 
metabolism, thereby decreasing the anticoagulation effect (Ansell et al., 2004; Kampouraki & 
Kamali, 2017). Conversely, acute use (binging) decreases warfarin metabolism due to the extra 
demand on the liver, which prioritises alcohol metabolism, thus allowing more of the unbound 
drug into the circulation and increasing the anticoagulation effect (Ansell et al., 2004; 
Kampouraki & Kamali, 2017). 
Advice on consumption of green leafy vegetables is inconsistent, leading to patient and 
clinician misunderstandings (Dennis, L Ripley, Planas, & Beach, 2008; Inge, 2015; Kampouraki 
& Kamali, 2017; Leblanc et al., 2016; Sheps, 2015). While evidence-based publications and 
56 
 
consumer advice leaflets advise that vitamin K-rich foods are not to be avoided (as the key goal 
is for a stable intake), there is considerable evidence that this advice is not well understood 
(Ansell et al., 2004; Dennis et al., 2008; Kampouraki & Kamali, 2017; Kneeland & Fang, 2010; 
Leblanc et al., 2016). A large (n = 1,069) study of warfarin-user understanding in this regard was 
conducted in Canada across 17 hospital sites with 68% of participants reporting they had been 
instructed to limit, or avoid, vitamin K-rich foods (Leblanc et al., 2016). Similarly, 90% of 
warfarinised patients in an earlier, smaller study in Slovenia (n = 214) had limited their 
vegetables intake, believing these were only an ‘occasional’ food (Mavri, Ostasevski Fernandez, 
Kramaric, & Kosmelj, 2015). 
There is scant information in the published domain regarding patients’ management of 
alcohol consumption and warfarin. However, just over half (57%) of participants in a qualitative 
study (n = 28) across the UK, USA and Spain involving long-term warfarin users (mean 6 years) 
reported that alcohol restrictions negatively affected their leisure and social activities (Murray, 
Wild, & Reaney, 2005). This negative impact was only felt by a quarter of patients (28%) in a 
later investigation in the UK (n = 115) (Atrial Fibrillation Association and AntiCoagulation 
Europe (UK), 2012). The fact that ‘young’ in the context of published anticoagulation studies 
appears to mean those in the 50–60 year mean age range (Davis, Billett, Cohen, & Arnsten, 
2005; Locadia, Sprangers, de Haes, Buller, & Prins, 2003), with warfarin most commonly 
prescribed for AF, stroke and deep vein thrombosis prophylaxis, and the prevalence of these 
diseases in HICs increasing with older age, may explain this absence (Ansell et al., 2004; Gallus 
et al., 2000). Certainly in Australia, alcohol use has been identified as an integral aspect to group 
identification and socialisation, particularly amongst young people (Roche et al., 2009). 
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However, the only published warfarin information specific to adolescents and younger adults 
located to date is from the Seattle Children’s Hospital ("Warfarin: What Adolescents and Young 
Adults Need to Know," 2016). This is a brief two-page brochure covering alcohol and 
recreational drug use, tattoos and body piercing, and birth control, with the key message that it is 
critical for patients to ensure their medical team is consulted and/or kept informed ("Warfarin: 
What Adolescents and Young Adults Need to Know," 2016). 
Medical surveillance.  
Attending clinics or doctors’ rooms for INR monitoring, medication adjustments, and 
medical checks can be time consuming, even in optimal HIC conditions. A UK study noted that 
most patients (81%) had their INRs completed within an hour or less (Atrial Fibrillation 
Association and AntiCoagulation Europe (UK), 2012). However, travelling to the clinic and the 
frequency of INR testing substantially increased time requirements (Atrial Fibrillation 
Association and AntiCoagulation Europe (UK), 2012). Nonetheless, the amount of time spent on 
INR monitoring ranged from six to 52 hours per annum, with people who worked the most 
affected; 54% of participants perceived this to negatively affect their employment (Atrial 
Fibrillation Association and AntiCoagulation Europe (UK), 2012). Similarly, while Murray, 
Wild and Reaney (2005) found that INR monitoring was a ‘burden’ for less than half of patients 
(43%), almost two-thirds of employed patients reported a higher burden than those not employed 
(63% vs. 31%) (Murray et al., 2005). 
Female reproduction risks and pregnancy considerations.  
Even in HICs, women requiring VR who have not completed their families or who intend 
to have children have a difficult decision to make when selecting valve prosthesis (Elkayam et 
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al., 2016a). Selecting a biological valve lowers the risk of thromboembolism, negates the need 
for anticoagulation, and eliminates the reproduction issues a mechanical valve imposes (Ashour, 
Shawky, & Hussein, 2000; Bonow et al., 2008; Nishimura et al., 2017; Walsh et al., 2008). 
However, accelerated structural valve deterioration associated with biological valves in younger 
people comes with a reoperation risk of 50% at between 10 and 15 years (Baumgartner et al., 
2017; Elkayam et al., 2016a; Elkayam, Goland, Pieper, & Silverside, 2016b; Regitz-Zagrosek et 
al., 2011). Consequently, women in HICs continue to have mechanical valves implanted, and 
accept or take measures to avoid the risks of pregnancy (Ashour et al., 2000; Elkayam et al., 
2016a). This has contributed, in part, to the development and evolution of guidelines for the 
management of anticoagulation-related, high-risk pregnancies, benefiting those in countries 
without the resources to offer valve reoperation as a choice (Ashour et al., 2000; Nanna & 
Stergiopoulos, 2014; Regitz-Zagrosek et al., 2011; Sliwa, Johnson, Zilla, & Roos-Hesselink, 
2015). 
Nonetheless, in HICs, patients who have mechanical valves implanted are still counselled 
to avoid pregnancy but if choosing to take the risk, conception should be planned and the 
pregnancy managed within a multidisciplinary team at a specialist centre, including a 
cardiologist and an obstetrician experienced in the management of such high-risk pregnancies 
(Ashour et al., 2000; Bouhout et al., 2014; De Santo et al., 2005; Regitz-Zagrosek et al., 2011; 
Sliwa et al., 2015). Clearly, both of these options have potentially greater ramifications in some 
LMICs where societal values and cultural roles are intrinsically linked to family and 
reproduction, and/or without such specialist resources, thus further amplifying the risk (Ashour 
et al., 2000; Chandra-Mouli, McCarraher, Phillips, Williamson, & Hainsworth, 2014; Dyer & 
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Patel, 2012). 
Antithrombotic therapy and bridging in pregnancy. Hemodynamically, women with 
mechanical valves tolerate pregnancy well (Elkayam et al., 2016a; Regitz-Zagrosek et al., 2011). 
The anticoagulation requirement, alongside the hypercoagulable state of pregnancy, heightens 
the risk of valve thrombosis, miscarriage, haemorrhagic and foetal complications (Ashour et al., 
2000; Elkayam et al., 2016a, 2016b; Nanna & Stergiopoulos, 2014; Regitz-Zagrosek et al., 
2011). There is no optimal anticoagulation agent that is deemed completely safe throughout all 
stages of pregnancy and all three anticoagulation agents have drawbacks (Elkayam et al., 2016a, 
2016b; Nanna & Stergiopoulos, 2014; Regitz-Zagrosek et al., 2011). Warfarin is the most 
effective drug for preventing thromboembolism; however, use during the first trimester carries 
an estimated 15% to 56% risk of miscarriage and a 1% to 30% risk of foetal embryopathy 
(Elkayam et al., 2016a; Regitz-Zagrosek et al., 2011). 
Unfractionated heparin (UFH), the most commonly available heparin in LMICs, does not 
harm the foetus but carries a high risk of thromboembolic complications to the mother (Regitz-
Zagrosek et al., 2011). Use of UFH instead of warfarin throughout pregnancy results in an 
estimated 33% rate of valve thrombosis; its use only in the first trimester and warfarin for the 
rest of the pregnancy (excluding the delivery phase) reduces valve thrombus to 9.2% (Chan, 
Anand, & Ginsberg, 2000). Additional complications of UFH are the risk of thrombocytopenia 
and osteoporosis (Regitz-Zagrosek et al., 2011). 
Currently, use of LMWH in the first trimester is cautiously recommended by some 
clinicians, provided the therapeutic marker for this, anti-Factor-Xa (AFXa), is continuously 
monitored and doses adjusted to remain in the therapeutic range (Elkayam et al., 2016a; Regitz-
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Zagrosek et al., 2011). Foetal wastage and embyonopathy ranges from 3% to 10% (Panduranga, 
El-Deeb, & Jha, 2014; Regitz-Zagrosek et al., 2011). Use of LMWH throughout pregnancy 
remains controversial due to scant evidence and unknown variables such as optimal AFX-a 
levels, measuring peak versus trough, and the fact that valve thrombus rates even during the first 
trimester have been reported to range from 3.6% to 9% (Regitz-Zagrosek et al., 2011). The 
absence of AFX-a measuring facilities in LMICs, even if LMWH is available, further reduces the 
potential of this drug for antithrombotic management during pregnancy (Panduranga et al., 
2014). 
Finally, there is some evidence, and cautious recommendations for the continued use of 
warfarin throughout a pregnancy, if the mother can remain in the target INR range on 5mg of 
warfarin or less with ‘foetal wastage’ at similar levels to management with LMWH (Elkayam et 
al., 2016a; Regitz-Zagrosek et al., 2011).  
Sporting restrictions and considerations.  
The prohibition on engaging in sports with ‘any risk of bodily contact’ arises from the 
serious haemorrhage risk secondary to anticoagulation (Bonow et al., 2015; Mellwig et al., 2008; 
Pelliccia et al., 2005). Sports in this category include motor racing, softball, basketball, body 
building, skiing, wrestling, boxing, cycling, hockey, soccer, and rugby (Nishimura et al., 2017). 
This may pose unacceptable constraints to males, particularly in LMICs in the Pacific Island 
regions where competitive contact sports, such as rugby, are socio-culturally important (Besnier, 
2014). While prosthetic valves place all patients as high risk for IE, in terms of sporting activity, 
any active infection with fever heightens IE risk, with guidelines cautioning resumption of 
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activity only once the inflammatory process has completely ceased (Bonow et al., 2008; 
Nishimura et al., 2008; Nishimura et al., 2017; Pelliccia et al., 2005). 
Section Four. Research Context 
The Fiji Islands.  
The research contained within this thesis investigates the outcomes for Fijian people who 
have had mechanical VR surgery for RHD performed in-country by Open Heart International 
(OHI), formerly Operation Open Heart. Commencing in 1990, OHI has established a strong VR 
surgical service, and have conducted 24 cardiothoracic, humanitarian, surgical missions during 
that time as the Fiji Islands do not yet have an in-country cardiothoracic surgical service.  
The Fiji Islands have one of the highest rates of RHD in the world. During 2008, 
screening of schoolchildren in Fiji identified 11 cases per 1,000 children in the five to 14-year-
old age group; at the time, this was the second-highest recorded prevalence of RHD globally 
(Colquhoun, 2009). This rate was much higher than the RHD cumulative incidence of 21 per 
100,000 population, calculated in an earlier retrospective assessment using the Fiji RHD 
surveillance system for 1996–2004 (Cuboni, Finau, & Cuboni, 2006). 
Geographical and sociodemographic context. The Fiji Islands (Fiji) are located in the 
middle of the Pacific Ocean and consist of 330 islands, of which a third are inhabited (Fiji 
Islands Bureau of Statistics, 2008). There are two main islands, Viti Levu and Vanua Levu, and 
87% of Fiji’s population live in these regions. There are three major cities: Suva (the capital), 
Lautoka on Viti Levu, and Labasa on Vanua Levu (Roberts et al., 2011). In 1874, the British 
Empire made Fiji a British Colony (Wikipedia, 2017). In 1970, Fiji gained independence and 
became a Commonwealth realm. However, after two military coups in 2006, it became a 
Republic under Commodore Frank Bainimarama (Wikipedia, 2017). In 2014, an election was 
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held with Commodore Bainimarama’s party winning the majority vote, which was confirmed as 
legal by international independent observers of the electoral process (Wikipedia, 2017). 
Fiji has an estimated population of one million people with two main ethnic groups: 
iTaukei (formerly indigenous Fijians, 57%) and Fijians of Indian descent (formerly Indo-Fijians, 
37.6%) (FIBS, 2008; Wikipedia, 2017). The distribution of both the total population and the two 
main ethic subgroups is roughly equal between rural and urban areas (FIBS, 2008; Wikipedia, 
2017). The remainder of the population is classified as ‘other’ and includes a substantial Chinese 
population, as well as Europeans and Pacific Islanders (FIBS, 2008; Wikipedia, 2017). English is 
the official language, although both Hindi and Fijian are taught in schools as part of the 
curriculum (FIBS, 2008). 
Fiji is classified as a LMIC and is ranked 96 in the World Health Organization’s (WHO) 
ranking of the world’s health systems, with life expectancy at birth for females being 66.8 years 
and 63.8 years for males (The World Bank, 2016; WHO, 2009). Poverty is a major problem, 
with 35.6% of Fijians of Indian descent and 34.2% of iTaukei classified as living in poverty 
(FIBS, 2008). Annual infant mortality rate is 18 per 1,000 live births, and for children under five, 
it is 22 per 1,000 (FIBS, 2008). The WHO classifies Fiji as having a generally good standard of 
health, compared to other Pacific Island counties, and Fiji has a MoH that is active in promoting 
and implementing health strategies (WHO, 2009).  
Health system. A comprehensive decentralised health system is managed by the MoH 
whilst retaining administration, human resource and finance as centralised components (Roberts 
et al., 2011). The health service structure is comprised of four divisional health services with 
smaller sub-divisional hospitals (SDH), Health Centres (HC), Nursing Stations (NS) and 
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Community Nursing Stations (CNS) feeding into these (see Figure 1) (Roberts et al., 2011). At 
the core of the health system structure are the Village Health and Community Health Workers 
(Roberts et al., 2011). All consultations, admissions, diagnostic and laboratory tests, and 
medications are free if dispensed at one of the above facilities (Roberts et al., 2011).   
The Colonial War Memorial Hospital (CWMH), located in the capital city of Suva, is the 
tertiary referral centre for Fiji and extends its services to surrounding Pacific Island countries 
(Roberts et al., 2011; Steer, Jenney, et al., 2009). CWMH is also the base where the OHI fly-
in/fly-out teams set up the cardiothoracic surgical service when in-country. Additionally, there 
are three other specialist hospitals: the P.J. Twomey Tuberculous and Leprosy Hospital, St Giles 
Psychiatric Hospital; and the Tamavua Rehabilitation Hospital (Roberts et al., 2011).  
The CWMH provides additional specialised services such as cardiac, renal and oncology; 
however, these are somewhat different to what HICs associate with these specialised services. 
For example, it was only in 2014, with the donation and installation of a cardiac catheterisation 
laboratory, that specialised cardiac services expanded to include cardiac angiography, 
angioplasty and permanent pacemaker implantation (on a user-pays system); cardiac stenting and 
balloon valvuloplasty remain unavailable. The oncology service includes basic surgery, some 
limited forms of chemotherapy and hormone treatment; however, patients requiring radiotherapy 
can only access treatment offshore, with the MoH providing funding for 20 patients annually 
(Ministry of Health and Medical Services, 2014).  
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Figure 2: Fiji health system structure 
Ministry of Health 
Centralised Administration, Human Resources, Supplies and Finance
Four Divisional Health Services 
Central and Eastern combined, Suva, Colonial War Memorial Hospital (CWMH)
Western in Lautoka (Lautoka Hospital) 
Northern in Labasa (Labasa Hospital) 
Subdivisional hospitals (SDH)
16 SDH
Each supervises a designated medical area
Average 12-40 beds. Provide inpatient care and outpatient services
Health Centres (HC)
77 HC
Managed by a medical officer or nurse practitioner
Staffed with 1-2 nurses
Reports to sub-divisional hospital
Nursing Stations (NS)  
101 NS
Staffed by one nurse 
Nurse conducts ‘outreach’ visits to designated nursing area 
Community Nursing Stations (CNS) 
Number of CNS varies
CNS complement and function like NS but are built and funded by individual 
communities, Need government approval and are run to government standards
Village Health Workers (VHW), Community Health Workers (CHW) 
Trained by MoH
VHW work in iTauki villgaes, CHW work in Fijian-of-Indian-Descent communities
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RHD in Fiji.  
RHD is recognised as a common cause of childhood mortality in Fiji, although actual 
numbers are unknown. This is partly because RHD is not a notifiable disease (Saunders, 2007; 
Steer, Kado, et al., 2009; WHO, 2008). However, one method used to estimate RHD deaths is 
retrospective autopsy data analysis. Singh et al. (2008) undertook a retrospective analysis of all 
autopsies (n = 6,218) conducted in Fiji during a 10-year period. RHD accounted for 2.5% of 
deaths, with the most common cause of death being heart failure (79%) (Singh et al., 2008). 
While the mean age of those who died from RHD was 38 years, 13% of RHD deaths were in 
children under the age of 15 (Singh et al., 2008). 
Hospitalisation for RHD is common and RHD mortality is high. Data on RHD and ARF 
presentations were collected prospectively by Steer et al. (2009) over a 23-month period from 
Fiji’s primary referring centre, the CWMH. The study identified 103 RHD admissions with a 
median age of 26.8 years. The most common cause of admission was heart failure (n = 52; 53%), 
with 9.7% (n = 10) dying during the admission period (Steer, Kado, et al., 2009). 
Echocardiographic information showed the mitral valve most frequently affected (89%), with 
MS present in 50% of patients indicating advanced RHD (Steer, Kado, et al., 2009). The 
youngest age identified with severe MS was 12 years (Steer, Kado, et al., 2009). 
During the Steer et al. (2009) investigation, younger people and female gender appeared 
more vulnerable to RHD, with 30% of the RHD admissions aged less than 20 years (Steer, Kado, 
et al., 2009). One quarter of all RHD admissions were pregnant (Steer, Kado, et al., 2009). 
Female patients were two-and-a-half times more likely to be admitted with RHD than males, 
66 
 
with many first diagnosed during pregnancy (Steer, Kado, et al., 2009). These findings were 
similar to an earlier study by Viali et al., (2006), which identified the prevalence of RHD among 
pregnant women in Fiji at 1.8 per 1,000 along with noting RHD as the second most common 
cause of maternal mortality in the country (Steer, Kado, et al., 2009; Viali, 2006). 
Methods for conducting research in a LIMC with operative services provided by a 
fly-in/fly-out surgical team.  
Both the setting and the modality of VR surgery delivery present additional challenges 
when conducting research in a LIMC. Maintaining data integrity provides one example of these 
challenges. As mentioned in Chapter One, obtaining institutional approval from OHI (Sydney, 
Australia) and the CWMH (Suva, Fiji) during 2005 in order to collate a continuing OHI patient 
database registry became integral to the conduct of research. By the time institutional and 
national Australian and Fijian HREC approval was obtained five years later in 2010, the primary 
database sources (operative and annual OHI reports) had been decimated by water damage after 
an inadvertent move to the OHI equipment shed during office relocation. Meanwhile in Fiji, the 
medical records department at CWMH had moved all patient records for the years 1990 through 
2006 into secondary storage. Secondary storage was an un-air-conditioned shipping container 
located at the back of the CWMH and upon investigation consisted of archival boxes stacked 
floor to ceiling with no shelves and no tracking system thus rendering these files inaccessible. 
Without the OHI patient database registry, the research within this thesis would not exist. 
Maintaining data integrity was not confined to the research. On the 2013 field trip, we 
began to encounter anomalies within the Fijian electronic patient record system (PaTIS) whereby 
deceased patients whose deaths had been verified from their paper files on preceding trips, began 
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appearing in PaTIS as still living. Once the MoH had been alerted, the OHI registry data was 
able to be used by the MoH RHD registry personnel to re-enter correct mortality and morbidity 
data. 
Summary of methodology. Whilst the specific methodology for each of the research aims 
is detailed within the relevant publication (Chapters 3 – 6) an overview is provided below in 
Table 1. 
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Table 1: An overview of study methodology  
 
HREC  HREC approval was obtained from the Sydney Adventist Hospital, the 
University of Technology#4, and the Fiji Ministry of Health, Human Research 
Ethics Committees in 2010 (Appendix A)  
 
Data extraction 
tool 
A data extraction tool was developed for the project, which included participant 
ID socio-demographic information, mortality and morbidity and which phases 
of the study they had completed 
 
Informed 
consent 
Written consent was obtained from all participants adhering to the standards 
prescribed in the Declaration of Helsinki 1964 (WHO, 2001) 
 
Recruitment  Patient details were obtained from the OOH Fiji surgical registry. 
Aim 1. At the start of each data collection cycle, patient records were reviewed 
at the CWMH. Visits were then made to referring hospitals, SOPD, and health 
clinics to extract additional information. Multiple patient records needed to be 
tracked, including accessing the centralised electronic record of patient visits 
and localised paper records at CWMH, referring hospitals, additional treating 
hospitals and separate out-patient departments, and village health clinic 
records. The last known villages of former patients were visited and familial 
and friendship networks utilised, to locate patients lost to follow up. 
Aim 2b. and Aim 3. A HRQoL survey was administered in-person to 
preoperative participants the day before VR surgery and at one year 
postoperative with the addition of the health-self management questionnaire for 
the pre-test/post-test group.   For the cross-sectional group, contact was 
initiated via phone or face-to-face during the OHI advance screening trips, at 
routine cardiac outpatient clinics at three major metropolitan referral centres, or 
at general health clinics in regional and divisional hospitals on the two main 
islands, Viti Levu and Vanua Levu.  Visits were made to the last known 
villages of former patients and familial and friendship networks were utilised to 
optimise patient follow-up.  The HRQoL surveys and health self-management 
questionnaires were interviewer-administered.   
Instrumentation  The data extraction tool was used for all fieldwork components of the study 
Aim 1. As above 
Aim 2a. The Critical Appraisal Skills Programme (CASP) tool 
Aim 2b. Health-related quality of life (HRQoL) was measured using the SF-36 
HRQoL instrument [25]. The SF-36 was designed to offer a concurrent 
measurement of physical and mental health status. It comprises 36 questions, 
which are weighted and aggregated to construct eight health domains: physical 
function; role limitations due to physical health (role-physical); bodily pain; 
                                               
4 The candidate commenced her doctoral studies at the University of Technology, Sydney in 2009 and transferred to the University of Sydney 
mid-way through her candidature, in 2014 
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general health; energy/fatigue (vitality); social function; role limitations due to 
emotional problems (role-emotional); and mental health [25].  Results from the 
SF-36 are provided by domain score as well as two summary composite scores: 
the physical composite score (PCS) and the mental composite score (MCS). 
Five points (or half an SD) score-difference is considered a moderate-sized 
effect.  
Aim 3. The anti-thrombotic health-self management questionnaire contained 
20 questions. Six questions related to oral anticoagulation knowledge and 
adherence, and were adapted from van Doorn et al., (2000) with seven 
additional questions related to heart clinic and RHD prophylaxis knowledge 
and adherence. A further seven were specific to the aftermath of having a 
mechanical valve prosthesis and were adapted from Perchinsky et al., (1998) 
however these did not end up in the analysis due to inadequate sample size to 
include. The complete 20-item questionnaire was piloted in Fiji during 2009 
along with the HRQoL instrument, with minor changes made for the local 
vernacular. 
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Chapter Three – Short- and Long-term Outcomes After Valve 
Replacement Surgery for Rheumatic Heart Disease in the South Pacific, 
Conducted by a Fly-in/Fly-out Humanitarian Surgical Team: A 20-Year 
Retrospective Study for the Years 1991–2011 
Preface  
This chapter presents the mortality and morbidity outcomes of the study thereby 
addressing Aim One of this thesis. The published paper of this study forms this chapter with 
contemporaneous research subsequent to the publication of the paper detailed in Chapter Seven. 
Author contributions to this paper are outlined in the ensuing author contribution statement. 
The HREC approval letters are contained in Appendix A. The Patient Information Sheet 
and Consent Forms are in Appendix B and C. 
The results presented in this chapter have been disseminated as follows: 
Published peer-reviewed papers  
Thomson Mangnall, L.J., Sibbritt, D.W., Fry M.M., & Gallagher, R.D. (2014). Short- and Long-
Term Outcomes after Valve Replacement Surgery for Rheumatic Heart Disease in the 
South Pacific, conducted by a Fly-in/Fly-out Humanitarian Surgical Team: a 20-year 
Retrospective Study for the Years 1991–2011. The Journal of thoracic and 
cardiovascular surgery.  148(5), 1996-2003. Impact Factor: 4.16 
Conference presentations  
Thomson Mangnall, L.J. (2016, March). Embedding Research Open Heart International. Why 
and what we know so far. Oral presentation at the NSW Critical Care Hot Topic Evening. 
'Critical Care out of the box; expand your Critical Care Nursing into third world 
countries'. Australian College of Critical Care Nurses. Sydney, Australia. 
Thomson Mangnall, L.J., Sibbritt, D.W., & Gallagher, R.D. (2016, September). Longer-term 
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Outcomes of Mechanical Valve Replacement for RHD in the Fiji Islands. Oral 
presentation at the 8th Annual International Congress of Cardiology, Barcelona, Spain.  
Thomson Mangnall, L.J., Sibbritt, D.W., & Gallagher, R.D. (2014, September). Fly-in/Fly-out 
volunteer surgical teams for tertiary treatment of RHD in the Pacific region. Oral 
presentation at the Rheumatic Heart Disease Forum at the 24th Annual World Congress 
of the World Society of Cardiothoracic Surgeons, Geneva, Switzerland. 
Thomson Mangnall, L.J. (2014, November). Valve replacement surgery for rheumatic heart 
disease in Fiji: what happens ‘after’? Oral presentation at The Cardiothoracic 
Conference, Sydney Adventist Hospital, Sydney, Australia.  
Thomson-Mangnall, L.J., Gallagher, R.D., Fry, M.M., & Windus, M. (2012, month?). An 
Australian-based outreach program of valve replacement surgery for rheumatic heart 
disease in Fiji: Early and Late Mortality and Major Adverse Valve-related events, Over a 
10-Year Period, 2001-2011. Poster presentation at the 60th Annual Scientific Meeting of 
the Cardiac Society of Australia and New Zealand (CSANZ) Brisbane, Queensland, 
Australia.  
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Chapter Four – Health-related Quality of Life of Patients After 
Mechanical Valve Replacement Surgery: An Integrative Review 
Preface 
Health-related quality of life (HRQoL) is an important outcome measure which was not 
able to be considered in the retrospective mortality and morbidity reporting in the preceding 
chapter. Additionally, the mortality and morbidity findings detailed in Chapter Three make it 
clear that adverse events are occurring not just in the postoperative period but over time. This 
reaffirms the need to investigate outcomes other than solely the historical 'gold standard' of 
mortality and morbidity. This chapter presents an integrative review of the HRQoL literature 
after mechanical VR in adolescents and younger adults thereby addressing Part A of Aim Two. 
The published paper of this review forms this chapter. Author contributions to this paper are 
outlined in the ensuing author contribution statement. 
The material presented in this paper has been disseminated as follows: 
Published peer-reviewed papers 
Thomson Mangnall, L.J., Sibbritt, D.W., Gallagher, R.D., & Fry, M.M. (2015). Health-related 
quality of life of patients after mechanical valve replacement surgery: An integrative 
review. European Journal of Cardiovascular Nursing. 14, 16–25. Impact Factor: 2.49 
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Chapter Five – Health-related Quality of Life of Patients after 
Mechanical Valve Replacement Surgery for Rheumatic Heart Disease in a 
Developing Country  
Preface 
The review in Chapter Four identified a lack of knowledge of the impact a mechanical 
VR and lifetime health needs may have on health-related quality of life (HRQoL) for younger 
people. This chapter reports the preoperative HRQoL and the postoperative HRQoL over time 
for adolescents and younger adults living in a LMIC, thereby addressing Part B of Aim Two. The 
published study forms this chapter. Author contributions to this paper are outlined in the ensuing 
author contribution statement.  
The HREC approval letters are contained in Appendix A. The Patient Information Sheet 
and Consent Forms are in Appendix B and C. The HRQoL instrumentation, license and approval 
to modify are contained in Appendices D and E. 
The material presented in this chapter has been disseminated as follows: 
Peer reviewed papers 
Thomson Mangnall, L.J., Sibbritt, D.W., Fry, M.M., Windus, M., & Gallagher R.D. (2014). 
Health-related quality of life of patients after mechanical valve replacement surgery for 
rheumatic heart disease in a developing country. Heart Asia. 6, 172-8. Impact Factor: 0.7. 
Conference presentations 
Thomson Mangnall L.J., Sibbritt D.W., & Gallagher R.D. (2016, September). Longer-term 
Outcomes of Mechanical Valve Replacement for RHD in the Fiji Islands. Oral 
presentation at the 8th Annual International Congress of Cardiology, Barcelona, Spain.  
Thomson Mangnall, L.J. (2014, November). Valve replacement surgery for rheumatic heart 
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disease in Fiji: what happens ‘after’? Oral presentation at The Cardiothoracic 
Conference, Sydney Adventist Hospital, Sydney, Australia.  
Thomson-Mangnall, L.J., Gallagher, R.D., Sibbritt, D.W., & Fry, M.M. (2013, month). Health-
related quality of life of people undergoing valve replacement surgery for rheumatic 
heart disease in Fiji. Poster presentation at the 23rd Australian Cardiovascular Health 
and Rehabilitation Association (ACRA) Annual Conference, Melbourne, VIC, Australia. 
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Chapter Six – Predictors of Warfarin Non-adherence in Younger 
Adults after Valve Replacement Surgery in the South Pacific  
Preface 
As discussed in Chapters One through Three, implantation of a mechanical valve 
prosthesis necessitates lifelong anti-thrombotic management with the only effective 
anticoagulant being warfarin. For people with mechanical valves there is only a very narrow 
therapeutic window which—along with the need to administer warfarin at a similar time daily, 
multiple interactions across various foods, medications, supplements, alcohol, kava and 
traditional medicines, lifestyle restrictions and requirement for medical surveillance of INRs—
results in warfarin being a drug well recognised as having adherence issues. Chapter Three 
highlighted the risk of bleeding and cerebral events for people living with a mechanical valve 
and this, along with the life-threatening consequences of non-adherence, emphasises the 
importance of investigating factors associated with adherence.  
This chapter reports the adherence rates and predictors of warfarin non-adherence 
identified in this study, thereby addressing Aim Three. The published paper of this study forms 
this chapter. Author contributions to this chapter are outlined in the ensuing author contribution 
statement.  
The HREC approval letters for this study are contained in Appendix A. The Patient 
Information Sheet and Consent Forms are in Appendix B and C. The questionnaire used in this 
study is contained in Appendix F. 
The results presented in this chapter have been disseminated as follows:  
Published peer-reviewed papers 
Thomson Mangnall, L.J., Sibbritt, D.W., Al-Sheyab, N., & Gallagher, R.D. (2016). Predictors of 
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warfarin non-adherence in younger adults after valve replacement surgery in the South 
Pacific. Heart Asia. 8, 18–23. Impact Factor: 0.7. 
Published abstracts 
Thomson Mangnall, L.J., Sibbritt, D.W., Al-Sheyab, N., & Gallagher, R.D. (2016). An Article 
Describing the Predictors of Warfarin Non-Adherence/Self-Cessation in Younger People 
Who Have Had Mechanical Valves Implanted for Rheumatic Heart Disease in One 
Pacific Island Country. Heart, Lung and Circulation, 25, S298. Impact Factor: 1.57. 
Conference presentations 
Thomson Mangnall, L.J., Sibbritt, D.W., Al-Sheyab, N., & Gallagher, R.D. (2016, August). 
Predictors of Warfarin non-adherence in younger people after mechanical valve 
replacement surgery in a low income country. Poster presentation at the 64th Annual 
Scientific Meeting of the Cardiac Society of Australia and New Zealand. Adelaide, South 
Australia.  
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Introduction to Chapter 
The Fiji Islands exemplify a LMIC setting with a high demand for VR surgery for 
patients who have had RHD without in-country cardiothoracic surgical capability. The research 
contained in this thesis aimed to identify short- and long- term outcomes of people who 
underwent mechanical VR surgery for RHD in Fiji conducted by a fly-in team. Patient outcomes 
investigated encompassed mortality and morbidity, HRQoL, and self-care in the key aspect of 
warfarin treatment. The research also sought to identify any subgroups potentially at risk of poor 
outcomes in all of these areas.  
The participants in this study form a unique cohort. These patients have received 
screening, surgery and care, from one volunteer, fly-in/fly-out cardio-thoracic surgical team, 
namely Open Heart International (OHI). OHI has been providing surgical services annually to 
the people of Fiji since 1990 with the 25th anniversary trip planned for 20185. These fly-in/fly-
out surgical trips provide specialised, cardiothoracic, surgical, clinicians across the spectrum of 
relevant disciplines (medical, pathology, sonography, anaesthetics, perfusion, intensive care, 
adult and paediatric nursing, physiotherapy) to deliver care, education and a great deal of the  
equipment and resources required, within a  three to four week period each year.  
The mechanical VR surgery, and related care, provided by the team indisputably saves 
lives and improves HRQoL as described within the publications contained in Chapters Three and 
Five. On the ground, and in real terms, patients (and their families) previously facing a grim 
prognosis, now have the opportunity to plan a future and resume work, study or step back into 
their previous societal role. The findings contained within the publications also established that 
                                               
5 OHI missions to Fiji did not occur in the years 1993 and 2014 due to CWMH operating suite renovations, 2000 due 
to political instability, 2016 the surgical trip was unable to proceed after the OHI advance screening team was 
stranded at Lautoka for a week and subsequently evacuated out of country due to Tropical Cyclone Zena forecast. 
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VR recipients often have residual issues with lifelong self-care needs to maintain their health and 
require regular skilled medical support. In a LMIC context as exemplified by this study in Fiji, 
the lifelong aftercare by patients, families and medical teams occurs in a setting of limited 
resources with VR patients managed through general cardiac out-patient clinics.   
Overall, key outcomes reported in this thesis provide evidence that the majority of people 
who underwent RHD VR surgery delivered by the OHI team, experienced significant and 
sustained improvement to their lives. Whilst such improvements are quantifiable in terms of 
HRQoL measures, resumption of schooling or employment there are also intangible positives 
such as restoration of hope and being able to plan a future.  
In recent years, RHD-related research has emerged as a dynamic field with many changes 
occurring at an international level including the World Health Organisation (WHO) executive 
board recommending a resolution for rheumatic fever and RHD to be included as a Global 
Health Priority at the World Health Assembly in May, 2018 (World Heart Federation, 2017). 
Consequently, it is timely that the research contained in this Thesis has identified areas where 
outcomes could be improved and subgroups of RHD VR patients who have experienced poorer 
outcomes. This chapter will summarise the key research findings and contextualise to 
contemporaneous research, discuss clinical implications, detail actions already commenced to 
assist in areas of deficit, outline the limitations and suggest future research.  
Whilst this research had three primary aims as described, reported and discussed in 
Chapters Three through Six, some aspects of the findings are intertwined, particularly in the 
areas relating to gender differences and the influences of time and age. Therefore, findings 
related to these areas will be discussed in greater depth in 'Implications for practice'.  
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Summary Aim One  
To determine the short- and long-term mortality and morbidity outcomes of all patients 
who have undergone mechanical valve replacement surgery for RHD, performed by an external 
fly-in/fly-out cardiac surgical team, in Fiji between 1991 and 2011, and identify independent 
predictors of these outcomes (Chapter Three) (Thomson Mangnall, Sibbritt, Fry, & Gallagher, 
2014). 
In Fiji, RHD is the sixth leading cause of premature mortality and whilst men generally 
are at higher risk of RHD-related mortality in that country, RHD is the second most common 
cause of death for pregnant women (Parks et al., 2015; Singh, Carapetis, Buadromo, Samberkar, 
& Steer, 2008). Data released after we had already published demonstrated the enormous costs of 
RHD both in monetary terms and personal loss (Heenan et al., 2014; Parks et al., 2015; World 
Heart Federation, 2017). Without timely intervention, annual mortality directly attributed to 
RHD is estimated at 10 per 100,000 person-years (3.7% per year) with almost half of these 
deaths occurring before the age of 40 years (Parks et al., 2015). Calculations of the economic 
burden imposed by this loss of productive life years to premature RHD mortality in Fiji alone, 
exceeded six million USA dollars annually (Parks et al., 2015). Earlier analysis of the full 
economic impact of RHD encompassing costs of mortality and morbidity such as diagnosis, 
hospitalisations, treatment and lost income, yielded a cost per patient annually of US$5500 
equating to 1.3 times the average annual gross domestic product per capita (Heenan et al., 2014). 
Thus VR surgery from a fly-in/fly-out surgical team provides the opportunity for a longer, 
healthier, life for patients living in LMIC's as exemplified by this research in Fiji, than would 
occur without intervention.  
Like any major surgical intervention, mechanical VR surgery has inherent associated 
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lifetime risks and this is one of many reasons why reporting of long-term outcomes is so 
important (Akins et al., 2008). The study reported in this thesis identified the patient sub-group 
most at risk of premature death, and morbidity events to be women, particularly if they had a VR 
and tricuspid ring annuloplasty.  
Effectively, one quarter (25.7%) of OHI patients sustained a morbidity event and/or died 
during the 20-year follow-up period reported in this aspect of the research. The highest risk 
period was during the first postoperative year with half of all mortality (11.97%, n=20) and 
morbidity (14.37%, n=24) occurring during this time. Overall, mortality causes were more often 
I.E and cardiogenic shock, whereas morbidity causes were more often thromboembolic and 
hemorrhagic. Within the critical first 90-days under standard reporting criterion (Akins et al., 
2008), females sustained more bleeding and cerebral morbidity events but more heart failure 
from mid- (91 days – 5 years) to late-term (5.01 – 20 years) follow-up, whereas men sustained 
more cerebral events during the mid-to-late term time-periods. 
There was substantial disparity in outcomes between males and females, with women 
three times more likely to die after VR than men. Given women were also more likely to undergo 
surgery, this means many women are at risk. At baseline, almost twice as many females (63%, 
n=106) as men (33%, n=61) underwent surgery, females were on average four years older (mean 
age 27.7 years, SD 12.5 years vs mean 23.3 years, SD 9.8 years) (Thomson Mangnall, Sibbritt, 
Fry, & Gallagher, 2014)  and a disproportionate number sustained a morbidity event and/or died. 
That is almost two-thirds of the study participants were females, but they accounted for a larger 
proportion (79.1%) of all morbidity and (81.3%) of all deaths. Patients identified to be at least 
risk of sustaining an adverse events were those who had an isolated VR. These patients were at 
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least two-thirds less likely to have a morbidity event, or to die, compared to people who had a 
mitral or aortic valve in combination with a tricuspid ring annuloplasty.  
An important aspect of understanding the  mortality and morbidity rates, which were 
comparable to VR data in HICs (Allareddy, Ward, Ely, & Levett, 2007), was that the average 
age of patients in this Fiji study was decades lower. Thus the impact of premature mortality and 
morbidity for participants in our study is a substantially higher loss of productive-life years 
(Bouhout et al., 2014).  
Contemporaneous research and practice.  
Since the publication of the mortality and morbidity outcomes included in the thesis in 
Chapter Three, (accepted for publication in February 2014), two further studies on mortality and 
morbidity outcomes of younger patients who have undergone mechanical VR surgery have been 
published in peer-reviewed literature.  Findings from a third study were presented at an 
international conference earlier in 2017 with manuscript publication pending. 
The earlier of these publications is author-described as a 30-year review (1983 – 2003) of 
cardiac surgery for valvular heart disease in a referral hospital in Ethiopia and is a retrospective 
chart review (Guteta, Yadeta, Azazh, & Mekonnen, 2016).  The data was sourced from the only 
public, adult, specialised cardiac clinic in the country, attached to the country's tertiary referral 
hospital, Tikur Anbessa Specialised Hospital (TASH) (Guteta et al., 2016).  The authors state 
that TASH commenced surgical management of patients with VHD in 2003. The valve surgeries 
were done at two hospitals in Ethiopia (Tikur Anbessa Hospital, Cardiac Centre for Ethiopia) 
and 11 other countries (locations not detailed in paper) (Guteta et al., 2016).  
There were 157 valvular procedures amongst the 112 patients in the study, 93.7% 
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(n=105) of patients had RHD etiology, of which 66% were female (n=74) and had a mean age of 
26 years (SD 8.1 years) (Guteta et al., 2016). Whilst patients having mechanical valve 
replacements are described as accounting for 73% of all procedures, the data is presented by 
valve procedure and position as opposed to procedure/position-per-patient. As a result, there is a 
lack of detail for comparison. The proportions of RHD patients having VR, whether the valve 
used was mechanical and how many had progressed from a repair to a VR are not reported (e.g. 
114 mechanical valves, 86 mitral, 28 aortic; 17 bioprosthetic valves, 11 mitral, 6 aortic; 26 valve 
repairs, 5 mitral, 2 aortic etc.) (Guteta et al., 2016). The authors note in their discussion, that 
valve procedure and valve type were informed by resources available because the VR surgeries 
were collaborations between TASH and "people" coming from Europe and North America 
(Guteta et al., 2016). 
In terms of outcomes, no mortality is mentioned, the absence of which would be highly 
unusual in any VR population over a 30-year period, suggesting that records retrieved perhaps 
were only from accessible, current, living patients, and thus prone to underrepresentation. 
Morbidity of the postop RHD patients was lower than in our study at just under 20% overall 
(n=22, 19.6%), comprising of heart failure (n=13, 11.6%), stroke (n=8, 7.1%) and AF (n=1, 
0.9%).  
The participant demographics, namely mean age and gender proportion are comparable to 
our study, however further comparisons are constrained due to absence of information on who 
received the mechanical valves, lack of mortality data and a breakdown of morbidity events by 
gender and postoperative time-period. 
The second study situated in the USA provided more detail of outcomes. Schnittman, 
137 
 
Itagaki, Toyoda, Adams et al. (2018) conducted a retrospective medical record analysis of 
survival and long-term outcomes of younger mitral VR patients aged 18 to 50 years (n = 2,727) 
in the USA. As their focus was on comparing bioprosthesis VR participant outcomes to 
mechanical VR outcomes, the majority of reporting is from the mechanical and bioprosthesis 
propensity score-matched (PSM) subsets (n = 373 each) (Schnittman et al., 2018). Mechanical 
VR patients comprised most of the overall sample (n = 2345, 86%). The mechanical VR PSM 
subset had a median age of 42 years (IQR 36-47 years), was predominately female (n = 233, 
62.5%) and had equal numbers of Caucasians (n = 183, 49.1%) to African-American and Other 
(n = 190, 50.9%). Actual mortality was only detailed at 30-day outcome and this was 0.8% (n = 
3) whereas ours was 2.4% (n = 4). Actuarial survival at 5-, 10-, and 15-years was 94.1% (95% CI 
91.2-96.1%), 88.8% (95% CI 85.1-91.6%) and 80.8% (95% CI 75.1-85.3%) (Schnittman et al., 
2018).  
Although recognising that actuarial survival and actual mortality are not the same 
outcome measures, comparison between Schnittman et al. (2018) data and our study data does 
provide some insight into potential differences in mortality outcomes between HIC and LMIC. 
Our reporting terms were different (5-, 10-, 20-years) so comparison can only be made between 
the 5- and 10-year time-periods. We had cumulative 5-, and 10-year mortality rates of 19.76% (n 
= 33) and 23.9% (n = 40) respectively, whereas extrapolating Schnittman et al. actuarial data to 
non-survival, provides estimated rates that are dramatically lower at 5.9% and 11.2% 
respectively. Morbidity outcomes between our study and findings reported in this paper are 
reported too differently to be able to make any form of comparison.  
Preliminary findings from an investigation undertaken by the Murdoch Menzies Institute 
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appears to further substantiate our findings of high rates of thromboembolic and haemorrhagic 
morbidity, premature death and female vulnerability to both (Colquhoun et al., 2017). The 
researchers from this initiative undertook a retrospective chart review of all patients who had 
undergone RHD-related mechanical VR in Fiji over a 5-year period from 2010-2014 (n = 123) 
with 109 records able to be retrieved (Colquhoun et al., 2017). Patients included in the study 
were those operated on by two separate fly-in/fly-out teams including OHI, as well as those who 
had surgery off-shore (Colquhoun et al., 2017). Almost a quarter (n = 29, 27%) of patients were 
identified as deceased and complications, particularly thrombotic in origin, were common,6 
mostly occurring between 30-days and one year post-operatively (Colquhoun et al., 2017). 
Additionally, being female and place of residence (remoteness) were identified as risk factors for 
worse outcomes.7 There are a small number of participants (n=32, 26%) that overlap between our 
study and the Menzies report for the years 2010 and 2011, possibly contributing to the similarity 
in findings. 
Summary Aim Two (b)  
To determine the pre- (2010 through 2012) and post-operative (1991–2012) HRQoL 
outcomes of all surviving and contactable patients who underwent mechanical valve replacement 
surgery for RHD, performed by an external fly-in/fly-out cardiac surgical team in Fiji, and 
identify independent predictors of these outcomes (Chapter 5) (Thomson Mangnall, Sibbritt, Fry, 
Windus, & Gallagher, 2014). 
English is the official language of Fiji and the Australian English language version of a 
                                               
6 Data cited from published abstract from conference proceedings. Personal communication with primary author to 
request specific data (n, %, significance level) was declined on the basis of intent to publish 
7 Personal correspondence with primary author and specific data unavailable for reasons as above. 
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the SF-36v2®, four-week recall version was used to quantify HRQoL (QualityMetric 
Incorporated, 2007). The SF-36v2®  is a standardised HRQoL measure designed to be used 
across diverse populations and disease groups to enhance generalisability and at time of selection 
for use, was the most frequently used measure in clinical trials (Scoggins & Patrick, 2009; Ware 
et al., 2007). Our RHD VR patients HRQoL was considerably impaired preoperatively but by 
one-year postoperative had improved significantly in seven of the eight domains measured. 
Importantly, all domain scores at this time point now matched or exceeded domain scores of the 
reference group, a healthy Pacific Islander population living in New Zealand (New Zealand 
Health Survey, 1999). Not only did overall HRQoL improve significantly, these improvements 
were sustained over time. 
There were four exceptions to the overall HRQoL trend in improvement over time and 
these were in aspects relating to mental health, aging, gender and valve.  Whilst the aggregate 
score for the domain of mental health made a clinical improvement of nine points from the 
preoperative measure, this change was not statistically significant thus mental health was the 
only domain that did not demonstrate significant positive change from preoperatively by one 
year postoperatively. At the two-year HRQoL time point, patients seemed to improve on mental 
health based on aggregate domain scores but in the regression modelling, this two-year time-
point independently predicted a decline in mental health. This may be a crucial time-period 
between one and two years is stage where patients need additional support and/or surveillance.  
The second exception was the association between increasing age and impairment in 
physical domains. With a mean participant age of 27-years in this component of our study, 
increasing age was an independent predictor of HRQoL worsening over time whereby for every 
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year increase in age, there was a one-third point reduction in the HRQoL score in the physical 
domains of bodily pain, role-physical and vitality. Thirdly, male gender was a predictor of a 
worse HRQoL outcome in the domain of role-emotional regardless of postoperative time-point, 
and finally, an isolated MVR was independently predictive of patients likely to have a worse 
HRQoL. 
Contemporaneous research and practice.  
The integrative literature review on HRQOL outcomes contained in Chapter Four and 
conducted as a precursor to the HRQoL component of this study was accepted for publication in 
February 2014. The HRQoL outcomes from this study, contained in Chapter Five, were accepted 
for publication in November 2014. There has been scant VR-related HRQoL findings focused on 
younger adults and/or adolescents and/or in LMIC, published over the ensuing three years.   
On repeating the search strategy, a single publication was identified which reported the 
findings of a study (n=100) of VR patients, from a university teaching hospital in Bangladesh 
(Aftabuddin, 2017). The study sample differed to our study in terms of the participants being 
almost a decade older (mean age 37 years, SD 7.4 years) and gender distribution was more equal 
(females 53%). Mitral stenosis was the predominant lesion with aetiology including RHD 
although this was not reported further. Forty of the VR8 participants were interviewed by phone, 
in-person, or via mail-survey at one-year post-operatively, using the Medical Outcomes Study 
(MOS SF-36). Although all domain scores were reportedly good, exceeding those of a gender 
and aged matched reference group, female gender and older age are described as predictors of 
significantly inferior scores across all of the SF-36 scales. However, specific data on the actual 
                                               
8 no separate data supplied for HRQoL subset demographics. 
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domain scores were not detailed, preventing direct comparisons with our study.  
Given the lack of an exact comparison group, congenital heart disease (CHD) survivors 
provide a reasonably similar population due to chronicity of an underlying cardiac condition, 
younger age and lifelong health self-management needs. A recent US study (n=208) of adult 
survivors of CHD (mean age 25.7 years, SD 7.1 years) investigating medical predictors of 
HRQoL using the SF-36v2®  identified three independent predictors of worse physical HRQoL 
and one for emotional HRQoL (Jackson, Hassen, Gerardo, Vannatta, & Daniels, 2016). Medical 
factors predictive of poorer physical HRQoL were a low family income hovering around the 
poverty threshold, taking two or more cardiac-related medications, and having a NYHA class 
higher than I, and for emotional HRQoL, it was NYHA of II or higher. 
Jackson et al., (2016) outcomes suggest being sicker and having fewer resources play a 
key role in poorer HRQoL perception. Whilst our findings indicate identify risk points for a 
slump in mental health (between 1 and 2 years postop) and a decline in physical domains over 
time associated with increasing age, Jackson et al., independent predictors of physical and 
emotional health are readily identified indicators of increased support needs thus warrant further 
investigation amongst younger VR patients.   
Summary Aim Three 
Determine anticoagulation (warfarin) adherence and predictors of non-adherence for 
surviving, and contactable people, who underwent mechanical VR surgery for RHD, performed 
by an external fly-in/fly-out cardiac surgical team in Fiji between 1991 and 2014 (Chapter 6) 
(Thomson Mangnall, Sibbritt, Al-Sheyab, & Gallagher, 2016). 
Poor adherence to warfarin taking was self-reported by a quarter of our patients, with 
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one-in eight self-ceasing completely. Younger patients were more likely to struggle in many of 
the areas of antithrombotic health self-management investigated, with a significant association 
between younger age and non-adherence. Patients who stopped taking warfarin also reported 
multiple issues with warfarin including fear of complications, and how the rigidity of warfarin 
timing interfered with their lives.  
The subgroup of patients most likely to discontinue warfarin were those who did not 
understand the reasons (knowledge gap), a history of forgetting to take warfarin (lack of 
embedded routine), and who had an extended travel time to, and from, the SOPD clinic (>1 
hour). These factors were all powerful influences with knowledge gap, lack of routine and 
extended travel being independently increasing the likelihood of warfarin cessation by 10-, 8- 
and 6-times (respectively). 
Contemporaneous research and practice.  
The adherence research summarised above and contained in Chapter 5 was accepted for 
publication in May 2016. Since then, a repeat search using the original strategy identified  further 
publications in peer-reviewed journals related to warfarin adherence in two LIMC, Jordon and 
Sudan (Ababneh, Al-Azzam, Alzoubi, & Rababa’h, 2016; Eltayeb, Mohamed, Elbur, & Elsayed, 
2017) .  
The study conducted in Jordan was cross-sectional  (n=331) and included two major 
hospitals, with a focus on adherence and effect on anti-coagulation control (Ababneh et al., 
2016).  Whilst not specifically focused on younger adults participant mean age was 56.7 years 
(SD 15.1) with an age range of 18 – 90 years and result reporting included younger (18-39 years) 
age divisions. The sample was gender-equal (females 53%, n=176) and one-fifth (n=69) were 
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VR patients. Literacy was low with almost half (46%, n=151) illiterate. Participants were 
recruited during warfarin prescription refills at the facility pharmacy. Two specifically trained 
interviewers conducted face-to-face interviews asking demographic and warfarin-related 
questions and applied the 8-item Morisky Medication Adherence Scale (MMAS-8).  
Overall 54% (n=178) of patients were classified as warfarin-adherent (Ababneh et al., 
2016).  Similar to our study, increasing age was also predictive of greater adherence, with people 
aged from 40 to 59 years more adherent (OR 3.08, 95% CI 1.33-7.03) than those aged 18 to 39 
years (OR 2.77, 95% CI 1.26-6.2). Likewise, patient understanding and knowledge also appeared 
to exert a significant influence with almost double the number of patients in the adherent group 
having received specific warfarin therapy counselling versus the non-adherent group (42% vs. 
26%, OR 2.06, 95% CI 1.29-3.30, p=0.002). Despite more than half of participants being 
adherent to warfarin therapy, only 15% (n=36) were found to be in the INR therapeutic TR 
greater than 70% of the time over the preceding year (Ababneh et al., 2016). These findings re-
emphasise that adherence is only one of many influences on attaining therapeutic TR. Although 
VKA therapy focuses on regular monitoring and warfarin dose adjustments, the narrow 
therapeutic window and inherent genetic variability in responsiveness, along with dietary 
interactions factors mean even adherent patients may still not attain optimal time in TR. This has 
the potential to demoralise patients and weaken adherence persistence.  
The similarly cross-sectional study (n = 93) was conducted in the Sudan (Eltayeb et al., 
2017). The study focus was to identify patient satisfaction with warfarin therapy along with 
warfarin adherence. Participants were classified as either being below (53%, n = 54), or above 60 
years of age (no other detail on age supplied), gender proportions were equal (50.5% female, n = 
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47), a quarter were illiterate (25%, n = 23) and almost two-thirds had a mechanical VR (61.3%, n 
= 57). Measures used were the abbreviated  Morisky 4-item medication adherence scale 
(MMAS-4) and included a 17-question anti-coagulation specific questionnaire, the oral Anti-Clot 
Treatment Scale (ATCS) in which 13 of the questionnaires explore the patient perceived burden 
of treatment:  the authors state they reverse-coded the ATCS so that higher scores measured 
satisfaction rather than burden (Eltayeb et al., 2017).  
Regardless of age group, half of patients (50.5%, n = 47) were classified as satisfied with 
warfarin therapy (<60 years, 48.1% satisfied, >60 years, 53.8% satisfied, p=0.588) but no 
correlation was found between patient-reported satisfaction and warfarin adherence with an 
extremely low number of patients identified as adherent at 5.4% (n = 5). Equally, no predictors 
of decreased adherence were able to be identified. Whilst patient satisfaction was reported by age 
group, adherence and predictors of satisfaction were not, meaning comparison to our study was 
limited. In light of the extremely low adherence rate in the study, it would be interesting to know 
how patient perceived burden would have correlated with poor adherence had the ATCS been 
administered as designed. The ATCS would be a potentially useful measure to apply in future 
research to identify correlations between burden and non-adherence, or warfarin cessation, 
amongst VR patients. 
Clinical Implications 
There are many aspects that influence health outcomes. For instance, the WHO classifies 
an individual's income, education, age, ethnicity, genetics, sexual orientation, social gradient and 
where the person lives, as major determinates of health (WHO, 2015). Some of these factors are 
classified as social determinants of health (SDH) (Braveman & Gottlieb, 2014; WHO, 2018a). 
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SDH's are the way a community, or country’s, social environment affects the health of the people 
living within that setting (Braveman & Gottlieb, 2014; Kreatsoulas & Anand, 2010).  
The WHO explains SDH as factors created by the forces and systems that shape the 
conditions of everyday life. These encompass global, national and local distribution of wealth, 
power and resources, political systems, social policies, social norms and development agendas 
(WHO, 2018b). How these factors are distributed generates the environment (e.g. 
neighbourhood, school, church, workplace) and conditions (e.g. social, economic and physical) 
into which individuals are born, grow, live, work, age and die (WHO, 2018b). SDH are crucial 
elements included in global health policies and programs, so much so that SDH are referred to as 
the ‘cause of the causes', meaning these are the factors that underpin the conditions that create 
risk factors for poorer outcomes (Kreatsoulas & Anand, 2010; WHO, 2018b). The WHOs current 
top 10 key concepts for SDH are detailed in Table 2 (WHO, 2018b). Of these, 'women and 
gender equity', and 'health systems' emerge as SDH factors relevant to the current study along 
with the general health determinants of 'social gradient', age, education and country ('where the 
person lives').  
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Table 2: The WHO 10 key concepts for the Social Determinants of Health (WHO, 2018b) 
Determinant  Concept  
Employment and 
working conditions  
How an individual's social position and the ways the type of job, under employment 
or threat of losing their job influences health 
 
Social exclusion Constantly changing, multi-dimensional processes where unequal power 
relationships in economic, political, social and cultural domains interact across a 
continuum of inclusion and exclusion. This is pervasive across all levels of society: 
individual; household; group; community; country; global. Inclusion and exclusion 
cause health inequities arising from unequal access to resources, capabilities and 
rights. 
 
Public health 
programmes and 
social determinants 
Addressing social determinants of health are a key factor in achieving health targets 
yet are often ignored by public health programmes. It is critical to identify the 
social determinates of health and healthy equity issues specific to the region where 
public health programmes are conducted, and that those public health programmes 
ensure support is inbuilt to address the identified issues.  
 
Women and gender 
equity 
The magnitude of the problem of gender inequity is vast and the consequences of 
inaction dire. The damage incurred to the physical and mental health of millions of 
women and girls globally is incalculable thus implementing actions to address 
women's rights to health and improve gender inequity is one of the most directive 
and effective ways to reduce health inequities and ensure effective use of health 
resources.  
 
Early child 
development 
The most important developmental period in life occurs in early childhood. This 
includes all equally important developmental aspects such as physical, social, 
emotional, cognitive, language. Deficits in this life stage strongly negatively 
influences future mental and physical health and well-being in such diverse areas of 
growth stunting, obesity, literacy and numeracy, criminality and lifelong economic 
participation  
 
Globalisation  How globalisation’s dynamics and processes such as trade liberalisation, and 
integration of production of goods affects health outcomes. 
 
Health systems The design, financing and operating of health systems are powerful health 
determinants. In order to improve health equity outcomes, evaluations and evidence 
of the effectiveness of different health system models are required. Focusing on 
innovative approaches that incorporate social determinates of health and bringing 
them to the public knowledge domain is integral to overcome social barriers to 
health.  
 
Measurement and 
evidence 
The development of methodologies and tools for measuring the causes, pathways 
and health outcomes of policy interventions. 
 
Urbanisation  Wide-ranging policies focused on healthy urbanisation encompassing factors that 
stimulate job creation and are designed to improve land tenure and land use, 
sustainable transportation and urban development, and provide better security 
through social protection, community empowerment and vulnerability reduction. 
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The influence of living context on health outcomes.  
Poorer economic and social circumstances are well-recognised to negatively impact 
health throughout life (Wilkinson & Marmot, 2002). Fiji was classified as a LMIC during the 
conduct of this research, with an average annual income of $6000 (US) and over a third (35%) of 
people living below the poverty line (The World Bank, 2016). In Fiji and other LMICs with no 
in-country cardiothoracic surgical capability, visiting surgical teams like OHI, often provide 
RHD sufferers with their only opportunity for VR surgery and the possibility of resuming a 
productive life.  However, once surgery and recovery are complete, associated specialised 
lifelong health requirements thereafter, have to be navigated in a setting without specialised 
resources. As discussed in Chapter Two, the standard HIC postoperative trajectory includes 
lifelong continuity of care in a controlled setting. There is a wide gap between HIC and LMIC in 
the ability to make and change appointments, see the same cardiologist for annual specialised 
medicals, the same GP/GP practice nurses for regular general checks, INRs, warfarin and 
medication adjustments, or any other aspect of health that is a concern, being reminded of 
medical or clinic appointments and telephone follow-up if appointments missed,  
Nonetheless, the positive benefits of being able to access and receive VR surgery for 
RHD at zero medical cost to the patient — despite the long-term risks and hurdles with 
management in a LMIC — cannot be overestimated. Data from LMIC such as the Ugandan RHD 
Registry surgical-needs evaluation, illustrate the urgent need for RHD VR surgery in many 
LMIC (Zhang, Okello, Nyakoojo, Lwabi, & Mondo, 2015). Out of 551 patients currently 
enrolled on that registry, 91.1% (n = 502) remain on medical management yet assessment of all 
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clinical factors using the ESC/EACTS valvular heart disease guidelines, demonstrated that 
63.3% (n = 349) urgently need surgical interventions of which 52.3% (n = 288) require VR 
surgery (Zhang et al., 2015). Despite a theoretical in-country capability, lack of skill and cost 
precludes surgery. Costs were exemplified by noting that the majority of Ugandans live on 
$1US/day or less, and an isolated VR done in-country costs in excess of $9000 US for the 
surgery alone (Zhang et al., 2015). 
The resource limitations, absence of specialised care, financial constraints, waiting and 
travel times, amongst other challenges encountered by VR patients residing in a LMIC, are not 
easily resolved. For Fijians, there is an additional consideration of being a highly mobile people. 
Maintaining family connections is a priority with considerable travel between kin compounded 
by very poor travel infrastructure: some islands only have irregular ferry services and others not 
at all, being completely dependent on private boat hire (Bola, 2017).  
One of the key implications for practice when surgery is delivered by a HIC team in a 
LMIC, is understanding the differences in management and care that LMIC VR patients will 
experience. Under these circumstances, preparing patients and equipping them with knowledge 
and written information tailored to their educational needs to enable them to become experts in 
their own care, becomes critical (Funnell, 2000; Pomey, Ghadiri, Karazivan, Fernandez, & 
Clavel, 2015). It is unrealistic to expect that they will encounter medical staff with experience or 
understanding of the unique challenges VR patients face in the LMIC setting. From our 
experience, incorporating a continual cycle of short and long-term health outcome evaluations 
enables collaborative tailoring of information as understanding of needs and knowledge gaps 
emerge over time.  
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Gender differences in VR surgical outcomes.  
The terms sex and gender are used interchangeably in the literature but they do have 
distinct meanings (Krieger, 2003). A person's sex is a binary classification based on anatomical 
and biological differences whereas gender arises from social and cultural conditioning of actions, 
boundaries, behaviours, and expectations for, and between, males and females, also referred to as 
gender, or cultural norms (Krieger, 2003; WHO, 2015). For the purposes of this discussion 
however, the term gender is used as an umbrella term to encompass the spectrum of physiology 
(e.g. menstruation, reproduction), social role (e.g. caregiver, wager-earner) and status (e.g. 
personal, cultural, family). The findings from the research contained in this thesis identified 
gender as a key marker of risk for different aspects of mortality, morbidity and HRQoL 
outcomes (Table 3).  
Table 3: Gender differences in outcomes after VR surgery for RHD patients in a LMIC 
 
Time point Risk At risk  
Early (1st 90 
days) 
Haemorrhagic events  Females 
 Cerebral events  Females 
Midterm  
(1–5 years) 
Premature death  Females 
 Heart failure hospital admissions  Female 
Late  
(5.01– 20 
years) 
Cerebral events  Males 
Overall  Haemorrhagic events  Females 
 Threefold increase risk of death Females 
 Worse HRQoL, emotional health Males 
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It is during adolescence and younger adulthood that gender norms are internalised and 
sex-differential mortality and morbidity patterns emerge thus the younger age of the participants 
in our study has important implications (Blum, Astone, Decker, & Mouli, 2014; Chandra-Mouli 
et al., 2017) (Kågesten et al., 2016). Globally, early pregnancy and childbirth complications, 
HIV/AIDS, unsafe abortion, infectious diseases, unintentional injuries, suicide and RHD are 
catalysts for significant mortality amongst adolescent girls and younger women (Chandra-Mouli 
et al., 2017; Kågesten et al., 2016; Zühlke et al., 2015). For adolescent boys and young men, the 
primary causes of mortality arise from road accidents, interpersonal violence, suicide, drowning 
and HIV/AIDS with younger males also more likely to engage in health-harming behaviours 
including illicit drug use, binge drinking, early and heavy smoking (Chandra-Mouli et al., 2017; 
Colquhoun, Azzopardi, Russell, Steer, & Patto, 2016; Kågesten et al., 2016).  
There are many factors that explain gender differences when interpreting research 
outcomes, however, a key factor is gender inequality (Kågesten et al., 2016). Whilst gender 
inequalities affect the lives of both males and females, females are disproportionally affected 
(WHO, 2015). Gender or cultural norms can result in gender inequalities whereby access is 
reduced to resources needed for better health including economic (income, savings), social 
networks (emotional health, social engagement), political (government, local, village leadership, 
participation), information and education (academic opportunities, literacy), time (access to 
health services), internal (sense of self in social or familial order, self-esteem) (Kågesten et al., 
2016; WHO, 2015). 
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Female gender.  
Globally around two-thirds of RHD diagnoses are female (AlFaleh et al., 2016; 
Lawrence, Carapetis, Griffiths, Edwards, & Condon, 2013; Ogah et al., 2015) as was reflected in 
the gender mix in our study, indicating that women are more at risk, possibly for multiple 
reasons. Female susceptibility to RHD has significant implications for VR patients in LMIC 
where there is a confluence of risk: RHD occurring during peak reproductive years, societal 
expectations to have children, very low use of contraception, limited expertise to manage 
pregnancy anti-coagulation needs and lack of specialised cardiothoracic or obstetric services 
(Nanna & Stergiopoulos, 2014; Panduranga, El-Deeb, & Jha, 2014; Regitz-Zagrosek et al., 2011; 
Sliwa, Johnson, Zilla, & Roos-Hesselink, 2015; Zühlke et al., 2015). All of these concerns 
remain post VR and likely contribute to the poorer mortality and morbidity outcomes for females 
in our study. 
Recent research from China on the pathophysiology of RHD provides one potential 
explanation as to why RHD occurs more frequently in women. Xiao, Zheng, Yang et al., (2017) 
studied excised rheumatic aortic valves (n = 39, 19 males, 20 females) (Xiao et al., 2017) and 
reported that valves from females exhibited a substantially higher inflammatory response along 
with higher levels of infiltrationary markers. Together these factors along with underlying 
sophisticated expressions of inflammatory genes are associated with accelerated valvular stenosis 
(Xiao et al., 2017). Cellular pathophysiology offers a possible explanation for female over-
representation in our study but the physiological implications of antithrombotic therapy for 
reproductive-age females may also contribute to their overall overrepresentation in haemorrhagic 
events. Whilst there are a number of studies focused on the risks of and considerations for 
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pregnancy management during VKA, as discussed in Chapter One, there were very few sourced, 
that examined biological considerations and/or lifestyle effects for young women needing to 
concurrently manage menstruation and contraception, and none in LMIC (Huq, Tvarkova, Arafa, 
& Kadir, 2011; Schwarz & Longo, 2012; Webster, Morse, & Bhatti, 2017).  
Effect of warfarin on menstruation. The effect of VKA on menstrual patterns appears to 
be substantial and disruptive to the point that women are making risky decisions such as 
discontinuing contraception, or reducing warfarin, in attempts to reduce disruption (Huq et al., 
2011). Huq et al., (2011) investigated the menstrual patterns of 47 young women (mean age 36 
years, range 20-50) from Caucasian, Black/Black African and Asian ethnicity before and after 
commencing on warfarin. Evaluation included a self-completed, validated instrument called the 
pictorial bleeding assessment chart (PBAC). All were being treated at a specialised 
anticoagulation clinic and all were within their INR TR throughout the study period. Just over 
half (55%, n=28) were on lifelong antithrombotic therapy. Half (n = 27) had a significant 
increase in mean duration of menstruation by an average of a day (mean duration from 5.4 to 6.6 
days) and two-thirds (66%, n=66) returned a PBAC score >100 indicative of heavy menstrual 
bleeding. There were also significant occurrences of intermenstrual bleeding, flooding and 
clotting with non-significant increase in numbers of post-coital bleeding events and anaemia. 
These outcomes resulted in more half of women (54.7%, n=29) changing their method of 
contraception. The numbers of women not using contraception doubled from 11 (23.4%) to 
22(46.8 %). One-third of women (36.2%, n=17) in the study, who did not want to become 
pregnant nonetheless took no contraceptive precautions despite 10 (21.3%) being on 
contraceptives when commencing warfarin. Additionally, without appropriate counselling and 
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medical support in managing increased flow (e.g. such as changing to progestin-containing 
contraceptives), evidence from the U.K suggests that many women will self-initiate reductions in  
warfarin dose in order to decrease menstrual flow with life-threatening consequences (Schwarz 
& Longo, 2012).  
Contraceptive considerations. Contraception is a key concern, as discussed in Chapter 
Two, with warfarin foetal teratogenicity, heightened miscarriage and increased thromboembolic 
risk arising from the increased hypercoagulable state of gestation, contributing factors to the high 
risks of VKA pregnancies, particularly when unplanned and without specialised obstetric and 
cardiology care (Schwarz & Longo, 2012; Vitale et al., 1999; Webster et al., 2017). A scarcity of 
relevant detail in our study meant we were unable to ascertain what proportion of haemorrhagic, 
cerebral, or mortality events were associated with pregnancy however, documentary evidence of 
13 live births from 23 pregnancies suggests this is an area which requires greater educational 
focus for patients and healthcare providers. Apart from concerns with contraception, and the 
implications of the aforementioned difficulties in managing menstruation, life-threatening 
haemorrhagic ovarian cysts are also a little known risk, estimated to affect one percent of women 
on VKA (Schwarz & Longo, 2012).  
Implications of cultural context and literacy. Anecdotal evidence and personal 
experience from patient follow-up in Fiji and Tonga also indicates that it is not simply a case of 
more education but rather identifying what patients and local healthcare providers understand 
from the information conveyed. Cultural context and literacy are but two of the variables that 
influence how patients action information given (Veronovici, Lasiuk, Rempel, & Norris, 2013; 
Wyber et al., 2014). This is especially important when information is being conveyed by people 
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who are not from the same cultural background as is the case with fly-in/fly-out cardiothoracic 
surgical teams, and when misunderstanding and miscommunications can have potentially lethal 
consequences (Sidhu, Gale, Gill, Marshall, & Jolly, 2015). An illustration of this has occurred in 
Fiji, where prospective female VR patients are informed by the surgeons and local physicians 
that if they are proceeding to have surgery they must ensure they do not get pregnant due to the 
risks, lack of specialised care and warfarin requirement. This advice is similarly repeated pre-
discharge and at follow-up clinics. On long-term follow-up, many patients 'take home message' 
was ' you can't have babies when you're on warfarin' so then have self-discontinued warfarin 
when they find out they are pregnant. This type of misunderstanding is then only identified when 
presenting to hospital for an antenatal check or to emergency with an embolic event.  
 Implications of societal role. The primary circumstances underpinning the overall higher 
risk of our VR female patients for poorer outcomes are likely to arise from a combination of 
health-seeking behavior and opportunities to access healthcare, related to societal role and 
cultural context. Gender inequities in health arise from culturally embedded, traditional societal 
perspective, of females as subordinate (Kågesten et al., 2016; Okojie, 1994; WHO, 2015). This is 
manifested in various ways: women's role as the bearer of, and primary career for, children; 
heavy domestic and/or paid workloads that create difficulties in having time to access healthcare; 
lack of, or reduced autonomy in decision making including their own bodies and financial 
access; women's instinctive desire to priorities their families over themselves concurrent with a 
patriarchal perspective as their needs being less important (Jayachandran, 2014; Kågesten et al., 
2016; WHO, 2015). 
Fijian society is organised along these traditional patriarchal lines with males as the head 
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of the household and, as such, controlling almost every aspect of their immediate and extended 
families (Kaitani, 2003; Peseckas, 2014). Social and economic roles are strongly influenced by 
gender and age along with complex hierarchical structures related to kinship amongst other 
factors (Peseckas, 2014). In rural areas, individuals roles and labor is clearly divided along 
gender lines: males attend farm work, fish, and attend construction and repair of dwellings; 
females tend to the needs of children, weave mats, wash cloths, cook and clean house (Peseckas, 
2014). These cultural aspects are likely to contribute to why women in our study were older than 
males at time of surgery, possibly indicating more advanced disease due to delayed diagnosis, 
which may in some part explain the significantly higher overall mortality and morbidity rate. 
Equally, with female mortality peaking at mid-term (1-5 years) along with admissions for heart 
failure being the predominant morbidity is equally suggestive of more advanced RHD at time of 
VR and/or further episodes of ARF creating lesions in other valves.  
Implications of poverty and distance. The lifelong health self-management requirements 
of VR surgery are time consuming in LMIC where it takes substantial amounts of time to get to 
anywhere. Consequently, females are likely to find it an insurmountable barrier to get to a 
monthly heart clinic for regular follow-up and to source their medications which are commonly 
more than just warfarin. Certainly in a large Indian cohort (n = 43,999) females were least likely 
to seek healthcare from medical professionals and more likely to use traditional medicine 
(Kanungo et al., 2015). It is unknown if this is also the situation in Fiji and requires further 
investigation. With 40% of the Fijian population living below the poverty line, it is also probable 
not having the funds to take a bus or catch a boat to get to clinic is an insurmountable barrier 
(Colquhoun et al., 2016). A study conducted on barriers to health care for women in Vanuatu 
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clearly identified a strong association between the wealth of a household and health clinic visits 
where those with a higher household income accessed these services more frequently (Kanungo 
et al., 2015). Despite potential explanatory answers for poor female outcomes, clearly further 
investigation is required to identify what Fijian women perceive as obstacles in the ways they 
access healthcare and attend to their own self-management.  
Male gender.  
In our study, males were at highest risk of cerebral events at late-term (5-20 years postop) 
and of worse emotional HRQoL overall. On data alone, the finding of higher male risk 
contradicts HIC evidence that women are at higher risk of stroke until it is understood that 
younger age is a confounder in such statistics (Caso et al., 2010; Turtzo & McCullough, 2008). 
Women have a higher stroke incidence because they live longer than men, stroke risk increases 
with age and women's risk equals men once they pass menopause (Caso et al., 2010; Turtzo & 
McCullough, 2008). Cerebral events post VR surgery can be ischemic or hemorrhagic, but may 
also be completely unrelated to the valve prosthesis thus (Raiten, 2011). A 10 year follow-up of 
mechanical VR patients identified etiological causes from 90 days postoperative, as being two-
thirds (77.5%, n = 69) hemorrhagic, 17% (n = 15 ) embolic and eight percent (n = 7%) non-
embolic lacunar infarcts (Raiten, 2011). Despite male gender being significantly associated with 
cerebral events at late-term, the group only consisted of five patients therefore we were unable to 
look for any other statistical associations. As this research is ongoing, we may identify reasons 
for this finding as we continue to collect data. Smoking is common amongst men in Fiji: whether 
this is a factor or if it is related to under-coagulation are aspects warranting further investigation.  
The overall lower scores in emotional HRQoL functioning for men in our study is an 
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interesting finding. Possible explanations may be related to the younger age of people in our 
study because with a mean age around 27 years, this is a life stage where peers are consolidating 
positions as head of households, marrying, having children (Colquhoun et al., 2016; Pinquart, 
2014; Verhoof, Maurice-Stam, Heymans, Evers, & Grootenhuis, 2014). Additionally at this 
younger age, stereotypical masculine norms of physicality, dominance and toughness are 
pronounced and as a VR patient on antithrombotic management regime, contact sports are 
prohibited alongside the need to regular attend clinic thus disrupting work and study 
opportunities (Bonow, Nishimura, Thompson, & Udelson, 2015; Kågesten et al., 2016; Mellwig, 
van Buuren, Gohlke-Baerwolf, & Bjornstad, 2008; Pelliccia et al., 2005). The disruption to work 
is a serious concern in Fiji when overall employment is only 59% and unemployment rates for 
people aged 15 to 24 is almost 20% (18.4%) (Colquhoun et al., 2016). A NYHA functional class 
greater than 1 was the only variable that was found to be predictive of impaired emotional 
HRQoL amongst a similarly aged (mean age 25.7 years) cohort of young adult survivors (n = 
218) of congenital heart disease (CHD) although this was not unique to male gender (Jackson et 
al., 2016). 
Support needs of mechanical VR patients change over time.  
Our mortality and morbidity, and HRQoL outcomes identified postoperative time points 
where additional patient support was clearly indicated. Whilst the evaluation time points were 
arbitrary (e.g. 30/60/90 days, 1/2/5 years onwards, and overall), events occur on an unpredictable 
continuum thus these time points signpost that surveillance and support needs for younger VR 
patients do not decrease with time (Table 4).  
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Table 4: Time points for increased surveillance and support for VR patients 
 
Time point Risk At risk  
Early  
1st 90 days) 
Death Females  
 Haemorrhagic events Females  
1 year Half of all deaths within 1st year All patients 
 Half of all morbidity within 1st year All patients 
2 years Time point independent predictor 
for worsening HRQoL, mental 
health domain 
All patients  
 Decline in HRQoL from 1 year 
(physical function, role-physical, 
role-emotional) 
All patients  
5 years Two-thirds of all deaths All patients  
Increasing 
every year 
Worsening perception of HRQoL 
physical health (domains of bodily 
pain, role-physical, vitality) 
All patients 
   
Developmental stage and HRQoL.  
The passage of time as an influence on increasing health-support needs has important 
clinical implications particularly for younger RHD VR patients where transitioning 
developmental stages are likely to play a contributory role to healthcare needs, and who have a 
longer lifetime in which to navigate this (Hole & Salem, 2016). The tasks that patients with 
chronic conditions do as part of everyday life generally change with developmental stage and 
thus the issues they face incorporating health self-management needs are likely to change 
accordingly (Markowitz, Garvey, & Laffel, 2015). This certainly appears to be the case for adult 
survivors of CHD. Recent evidence from an investigation (n = 133) in a similarly aged cohort 
(mean age 28.7, SD 6.83) exploring associations between psychosocial functioning, illness 
perception, disease severity and NYHA functional status, and age, found significant differences 
between CHD patients in their 20s and 30s, as well as between CHD patients and a healthy 
reference group (n = 117, mean age) (Enomoto & Nakazawa, 2015).  
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Overall there were similar levels of anxiety and depression between the CHD patients 
and the reference group; however, the CHD patients aged in their 30s were significantly more 
likely to be anxious and depressed, returned significantly higher scores on negative illness 
perception and a stronger need to 'be understood' than the CHD patients in their 20s and the 
reference group (all p<0.01). Yet, on the positive side, this older group scored significantly 
higher in terms of being independent of parents, less reliant on friends and with higher level 
problem-solving skills than the younger group (all p<0.01). Worse NYHA functional status was 
independently associated with higher levels of anxiety regardless of age. Patients with a NHYA 
II and III returned significantly higher anxiety scores and probable cases of anxiety than NYHA I 
(p<0.05) (Enomoto & Nakazawa, 2015). 
 Ambiguity towards an unknown future was associated with higher levels of anxiety and 
depression, with these increasing the longer CHD patients lived with their disease state, whereas 
the outcomes for the reference group was stable across their 20s, 30s, and 40s (Enomoto & 
Nakazawa, 2015). The authors conclude that psychosocial functioning (as measured by anxiety, 
depression, independence and dependence in relation to parents and friends, and problem-solving 
scales) is stable after their 20's in younger healthy adults but CHD patients have major, 
challenging, differences even after entering adulthood (Enomoto & Nakazawa, 2015).  
The measurement scales used by Enomoto and Nakazawa (2015) in their research are 
readily applied and are a useful consideration for future research in our younger VR patients. It is 
possible that in applying specific measures to our younger VR patients we may find similar 
issues in terms of mental health, illness perception and feelings of uncertainty towards the future. 
It is important to evaluate for similar effects particularly because we used a generic measure of 
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HRQoL, and overall, whilst our patients HRQoL worsened over time the primary association 
was in physical domains. Possible explanation for our worsening HRQoL physical domain 
scores may lay in an associated decrease in NYHA status as evidenced in this CHD study. It is 
noteworthy that the NYHA functional class was an independent predictor of higher anxiety 
because a later study, also of adult CHD patients (n = 218, mean age 25.7, SD 7.1 years) looking 
at medical factors that predict HRQoL, found that a NHYA class 11 or higher explained a 
quarter of the variability in poorer emotional HRQoL and was the only predictor isolated of 
worse physical HRQoL (Jorngarden, Wettergen, & von Essen, 2006) 
Regular and consistent systems for antithrombotic management and patient support.  
A regular and consistent system of anticoagulant access, surveillance including INR 
monitoring and follow-up is essential for better outcomes (Ansell et al., 2004) as our mortality 
and morbidity results so clearly illustrate. Whilst point-of-contact (POC) devices are an 
unrealistic option for patients in LIMC, a long-term study comparing POC to standard care 
(venepuncture INR monitoring) starkly illustrates the pronounced difference increased 
surveillance can make to outcomes (Mair et al., 2012).  
The study was set in Germany where a structured pre-discharge education programme is 
routine for all patients (Mair et al., 2012). Additionally all patients are given the option of having 
a POC device to self-manage INR checks and make their own nomogram-based warfarin 
adjustments to their individualised therapeutic TR. Those that took up the offer (Self-M) then 
had specialised training sessions on use of POC and nomogram. Patients who did not want a 
POC (Conv-T) were managed conventionally with venepuncture INR and their usual family 
doctor managed warfarin titration. Mair et al., conducted a retrospective follow-up on both 
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patient groups (Self-M, n=160, Con-T, n=260) with mean duration of 8.6 years (SD 2.1 years).  
The Self-M patients were within their INR TR range significantly more often than the Con-T 
(72.9% vs. 57.2%, p<0.0001); had a significantly higher frequency of INR testing (p<0.01) and 
significantly better (p<0.001) actuarial survival at one, five and 10 years (100, 99, 97 vs 100, 95, 
81, respectively) (Mair et al., 2012). Using multivariate aggression analysis with age, type of 
surgery, valve size, concomitant processes, AF and carotid surgery as the predictor variables, the 
only independent predictor of  mortality was Con-T, or the usual level of INR monitoring HIC 
patients expect (Mair et al., 2012).  Clearly patient self-managed INR and warfarin titration is 
only a proxy measure in terms of discussing the valve of increased surveillance and support for 
VR patients and, especially in LIMC, however these findings do show the remarkable outcomes 
that are possible. 
Application to research context.  
It is important to consider ways better surveillance and support this can be achieved in 
LMIC where existing resources are already lean and there are many competing demands 
(Nambiar et al., 2017). At the current time, adult SOPD patients in Fiji are not contacted if they 
miss their scheduled clinic, yet paediatric patients are. At the CWMH in Suva, the paediatric 
cardiac SOPD has the same volume of patients as the adult cardiac SOPD and the same clerical, 
nursing and medical staffing levels.9 A simple change to include the existing paediatric process 
to the adult side would not incur additional costs but would be a small step towards increasing 
patient surveillance and helping them to feel supported. 
Task-shifting or task-sharing (the more collaborative term), whereby lesser skilled staff 
                                               
9 On the ground observation and dialogue with the local medical, nursing and clerical staff in both areas at CWMH. 
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are trained to take on some of the health duties of higher skilled staff has been increasingly 
utilised in LMIC, but to be successful requires an upfront investment in evaluation, needs 
assessment, training, and ensuring supporting policies are in place (Dawson, Buchan, Duffield, 
Homer, & Wijewardena, 2014; Okyere, Mwanri, & Ward, 2017; Wiedenmayer, Kapologwe, 
Charles, Chilunda, & Mapunjo, 2015). In terms of task-sharing roles, Fiji has incorporated 
Master's- degree trained Nurse Practitioners with limited prescribing privileges, such as 
immunisation and RHD prophylaxis, in selected areas of public health (Pulcini, Jelic, Gul, & 
Loke, 2010; Usher & Lindsay, 2003).  
Excluding POC devices, available evidence suggests that the greatest single influence on 
INR control is a specialised anticoagulation, or warfarin clinic (terminology varies with study 
setting), regardless if the clinic is run by a doctor, a nurse-clinician or a pharmacist (Iung & 
Rodés-Cabau, 2014; Kneeland & Fang, 2010; van Walraven, Jennings, Oake, Fergusson, & 
Forster, 2006; Witt, Sadler, Shanahan, Mazzoli, & Tillman, 2005). Increasing the scope of NPs 
to run a warfarin SOPD clinic in each of Fiji's major hospitals would be a strategy that would 
provide an enormous benefit to all patients on anticoagulants with numerous warfarin titration 
nomograms available to guide evidence-based prescribing (Dumont, Mordasiewicz, Kosar, & 
Schuster, 2013; Perlstein et al., 2012).  
Our mortality and morbidity outcomes were provided to the Chief Paediatrician and Fiji 
MoH after publication in 2014. Subsequently, an email dialogue developed with a request from 
the Fiji MoH (via the CWMH Chief paediatrician) regarding the cost-feasibility of obtaining 200 
POC for SOPD clinics throughout the country; since that time, financial constraints and 
competing demands have resulted in this no longer being prioritised (Kado, 2014).  
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Knowledge, adherence and outcomes.  
The high prevalence of thromboembolic and haemorrhagic events identified in our study 
make it is crucial to understand factors that influence knowledge, adherence, and non-adherence. 
One of the barriers to understanding is that the majority of research exploring outcomes of VR 
surgery and VKA therapy adherence focusses on the older adult and therefore neglects the 
adolescent or younger adult and potential influences of more rapidly changing developmental 
stages (Greene et al., 2000; Sawyer, Drew, Yeo, & Britto, 2007). In particular, adolescents and 
younger adults differ from an older adult in their cognitive and emotional maturity, and in their 
independence, identity, lifestyle and educational needs (Colquhoun et al., 2016; Greene et al., 
2000; Sawyer & Aroni, 2005; Sawyer et al., 2007).  
The onset of adolescence has long been defined by puberty and physical growth with the 
end of adolescence marked by transitioning from dependent child to independent adult (Durkin, 
2005). Adolescence can’t be defined solely by age and definitions vary from 10 to 19 years 
(WHO) to 15 to 24 years (UN), (WHO, 2014). The term 'young people' as used by WHO, is 
intended to encompass adolescence and young adults from 10 to 24 years of age and is used to 
better reflect other adolescent developmental aspects such as neurocognitive maturation which is 
generally attained by the age of 24 (Colquhoun et al., 2016; WHO, 2014). Using this latter 
definition, there were clear differences above and below the age of 24 years in levels of warfarin 
adherence in our study, with younger people less adherent, thus reinforcing that developmental 
stage is an important consideration in terms of evaluating adherence and the tailoring of 
education and support strategies  
Enabling patients to be engaged with, and experts in, their own care, as mentioned earlier, 
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is recognised as integral to optimal health self-management, and is associated with increased 
adherence in other chronic diseases including similarly younger adults, such as those with type 1 
diabetes (T1D) (Monaghan, Helgeson, & Wiebe, 2015; van Houtum, Rijken, Heijmans, & 
Groenewegen, 2013). Our research findings indicate that many of the reasons recognised 
globally as contributing to poor adherence and/or subsequent self-cessation of medications in 
general - including lack of knowledge, frustrations with regular medication taking, medical 
surveillance requirements interfering with daily life, distance to facility, painful tests, and fear of 
adverse outcomes (Cruess et al., 2010; Sabaté, 2003) - were present for our younger VR patients.   
Intrapersonal insights.  
Qualitative research is important when seeking to understand the complex and 
multifaceted reasons intentional and unintentional non-adherence occurs  (PLoS Medicine 
Editors, 2007). A qualitative study (n=30) set in the UK, investigating reasons why younger 
people with T1D may have poorer adherence provides insights into the benefits of age-
appropriate, tailored country and disease-specific education, why knowledge gaps exist, how 
changing perspectives affect knowledge acquisition behaviour, and ways in which conflicting 
and contradictory disease information contributes to knowledge deficits  (Rankin, Heller, & 
Lawton, 2011).  
The participants in the UK study had a mean age of 36 (SD 11.6) with a mean duration of 
T1D of 16.5 years (SD 10.3 years) and all had attended intensive five-day, established, T1D 
management programme consisting of small groups (6-8), tailored to patients individual social 
and cultural needs (Rankin et al., 2011). Within a week of course completion, individual semi-
structured interviews were conducted exploring their perspectives on pre-course knowledge and 
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self-management amongst other aspects. Most participants expressed surprise at how poorly they 
had understood their disease and self-management prior to the course including not appreciating 
the serious repercussions in the short and longer term of ill-informed food, activity and insulin 
choice (Rankin et al., 2011).  
Explanation for previous knowledge gaps included diagnosis at a younger age which 
created a dynamic whereby the patient's reliance on natural parental control and illness 
management resulted in them becoming adolescents and young adults with limited self-
management skills, little sense of personal responsibility for their disease and deficits in 
knowledge acquisition skills (Rankin et al., 2011). Knowledge acquisition was described from 
various perspectives varying with life stage: teenage years were reflectively seen to be more 
about denial and risk-taking behaviours in order to fit in with peers and have what was perceived 
to be a normal life, whereas forming serious relationships or having children were viewed as 
catalysts for increased engagement with personal disease management. For other participants, 
feeling healthy or well, meant they attached little importance to diabetes information or glucose 
control and it was only when symptoms developed or adverse events occurred that disease-
specific information became relevant (Rankin et al., 2011). Other factors associated with 
knowledge deficits were viewed as related to lack of information and/or information assimilation 
of changing biomedical of disease  management over the years and receiving conflicting and 
contradictory information (Rankin et al., 2011).   
One of Rankin et al.’s, (2011) key findings was that the origins of patients knowledge 
gaps are a powerful determinant of how they engage with, and assimilate, the information 
provided. Findings such as these from other younger chronic disease populations, demonstrate 
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the need to also include qualitative methodologies in future VR patient research to firstly 
understand knowledge gaps then to collaboratively find better ways to deliver information.   
Clinical Practice Implemented During Research 
Throughout this research, as data analysis was completed and outcomes became known, 
small, yet important, collaborative strategies have been implemented during subsequent OHI 
surgical missions. One such example was the discovery that our VR patients were being 
stabilised in-hospital on a very low vitamin K diet, colloquially termed a 'leafy-greens exempt 
diet' and when reviewing medical records across the different regional centres reading medical 
orders to 'limit green leafy veg to three small serves a week' and 'no vegetables'. This was at odds 
with what our VR patients normal diet is with green leafy veg an integral part of the main meal 
of the day (evening): almost every home has a garden plot, and growing, consuming and/or 
selling vegetables (veg) is integral to Fijian life (Fink, Neave, Hickes, Wang, & Nand, 2013). 
Apart from being readily available and easily grown, vitamin K-rich veg form an important part 
of a balanced diet, regardless of place of residence (Leblanc et al., 2016; Yan, 2016). 
Consequently, limiting, or prohibiting, such an important nutritional source has negative 
consequences for overall health and INR stability (Leblanc et al., 2016).  
Collaborative clinical practice initiatives that have been implemented are detailed in 
Table 5. As previously noted, the research contained in this thesis is being duplicated in Tonga, 
consequently implementation of clinical practice initiatives is occurring in both countries 
differing by the schedule of each country's OHI team visits and influenced by the size of each 
country (Fiji has approximately ten times the population of Tonga) and the availability of in-
country personnel. For example, whilst we were able to commence the collaborative process for 
the development of country- and patient-specific warfarin and discharge information sheets in 
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Fiji during the OHI visit in 2015, these remain in draft for completion during the 2018 visit10 
whereas the same process was able to be initiated and completed during the 2015 OHI trip to 
Tonga.   
  
                                               
10 We were evacuated due to extreme weather conditions during OHI screening in Fiji during 2016 consequently no 
cardiothoracic surgical team visit occurred and during 2017 I was unable to participate in either the Fijian screening 
or OHI surgical team visit due to work and thesis time-constraints. 
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Table 5: Collaborative clinical practice initiatives 
 
Collaboration focus Clinical practice initiatives 
Collaboration with local and 
OHI team pharmacists and VR 
patients to identify local VKA 
rich food sources and dietary 
VKA antagonists 
- The construction of a country-specific patient warfarin 
information handout including food tables and dietary advice 
tailored to local food examples for the Tonga OHI patients 
commencing in 2015 with a Fijian-tailored handout in 
development for the 2018 OHI visit (Appendix G) 
 
Annual pre-operative meeting 
with the head hospital dietitian  
-Discuss rationale for inclusion of green leafy veg in diets of 
patients on VKA 
-Addition of green leafy veg to VR in-patients daily diet 
Collaboration with local 
physiotherapist, medical and 
nursing staff and VR patients to 
tailor discharge information to 
local setting  
-Development of country specific discharge information 
handout for the Tonga OHI patients commencing in 2015 with 
a Fijian-tailored handout in development for the 2018 OHI 
visit (Appendix H) 
  
Engagement of hospital 
administrators, and medical and 
nursing staff including 
consultants and trainees  
Annual Grand Rounds session during the time the OHI team is 
operating to: 
- share research findings and updated mortality and morbidity 
outcomes including Kaplan Meir survival curves 
-a presentation on the complexities of warfarin management 
including the need to assume 'the patient is innocent until 
proven guilty' in terms of assumptions about warfarin non-
adherence when INRs outside of therapeutic TR 
-RHD prophylaxis updates and education on continuation 
post-VR 
  
Integration with the RHD 
control programme 
-Bidirectional sharing of mortality and morbidity updates on 
individual patients in the RHD national registrar  
 -RHD liaison nurse practitioner notified when preoperative 
patients admitted for her to come across for RHD specific 
education including RHD prophylaxis and enrolment on 
registrar if not already in there 
Creating readily accessed 
evidence-based resources for 
medical and nursing staff, and 
interested VR patients  
A one terabyte Dropbox account set up and maintained by the 
thesis author providing access to up-to-the-minute reviews, 
international guidelines and publications related to: 
- VR and warfarin management including VKA titration 
nomograms and VR pregnancy management  
- IE management and prophylaxis 
- RHD prophylaxis  
- published outcomes of this research  
VR patient peer-engagement 
and support 
-Creation of a private Facebook groups. One was created by 
the 2015 patients and they named it 'Fight Club and the other 
set up by OHI in 2017 to provide access to clinical support 
from VR and RHD clinicians 
Limitations and Scope of Findings 
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The research contained within this thesis provides a unique contribution to the body of 
knowledge on short and longer-term health outcomes after VR surgery for RHD in a LIMC. 
Nonetheless, it is important to reflect on actual and potential limitations, when considering the 
implications and generalisability of these findings, and whilst these were detailed within each 
publication (Chapters 3 through 6) the key considerations are collated below. 
Participants and setting. Participants in this study were a very specific sample of patients 
living in an isolated Pacific Island country, having surgery performed by one surgical team. 
Whilst all participants were 'Fijians', the government classifies its own people by ethnicity so that 
participants in our study were a mix of i'Taukei (indigenous Fijians), Fijians of Indian Heritage 
(formerly Indo-Fijians) and small number of Other (classified as being of Chinese, European, 
mixed race, Rotuman or European origin). The diversity in the cultural mix may enhance the 
generalisability of our findings to other similarly mixed-ethnicity countries within the Asia-
Pacific region but may limit generalisability of findings from the prospective measures (HRQoL 
and warfarin adherence) where ethnicity can exert an influence on responses.   
Sampling considerations. There is a risk of bias with opportunistic sampling as was used 
in the HRQoL and adherence arms although this was largely mitigated because no potential 
participant declined enrollment along with an absence of statistical and descriptive differences 
between those enrolled and those not. A number of the prospective measures including warfarin 
adherence were by self-report. The use of self-report poses a risk of self-representational bias but 
conversely increases the likelihood of accuracy in the report of non-adherence and lower 
knowledge. An additional sampling constraint lay with the timing of the prospective measures. 
As these were only able to be attended when the researcher was in-country bi-annually, and not 
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all participants able to be contacted on each visit, some people died before they were able to be 
interviewed. It is possible that the outcomes of the prospective measures are worse than reported  
due to this constraint. 
Sample size and data constraints. Whilst we had adequate numbers to meet the 
requirements of the various statistical analyses planned for, and conducted, throughout this 
study, the overall sample size limited more advanced analyses and the inclusion of additional 
variables.  For example, we would have liked to analyze for associations between warfarin non-
adherence and HRQoL, or the presence of morbidities and non-adherence however our sample 
size precluded the ability to do this within the candidature time-frame. Data was occasionally 
incomplete, or absent, particularly in relation to clinical data and thus some factors that may have 
influenced outcomes, could not be considered, even at a descriptive level. The types of clinical 
data that was incomplete or absent included TTE findings, comorbidities, frequency of clinic 
attendance, and duration of prescription and refills for essential medications such as frusemide, 
digoxin and warfarin. Additionally, having a large number of deaths as ‘sudden and unexpected’ 
without having an identified cause reduced the ability to fully evaluate the causes of death, and 
consequently accurately compare the cause-of-death outcomes from this study, to other 
populations.  Finally, whilst the majority of participants at time of surgery were adolescents or 
younger adults (thus the focus of this research), there was wide age-distribution range (12 to 56 
years) and whilst this is reflective of both the virulence of RHD and the delay in accessing timely 
surgical intervention in this particular LIMC, the inclusion of these outliers may reduce the 
generalisability of our findings.  
Instrumentation. The current absence of disease-specific HRQoL evaluation instrument 
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for mechanical VR surgery meant the use of a widely-used, generic HRQoL instrument (SF-
36v2) was vital in the conduct of this study to enable comparison to other surgical and chronic 
disease populations. However, despite identifying the importance of including disease-specific 
questions alongside generic HRQoL in the integrative review in Chapter Three, sample size 
limitations constrained our ability to conduct further HRQoL analysis as mentioned above.  It is 
likely that other aspects of VR surgery HRQoL, such as valve noise, INR monitoring and dietary 
and social constraints imposed by the mechanical VR may also contribute to HRQoL and are 
indicated for future research. Additionally, use of validated adherence measures such as MMAS-
4 or MMAS-8, and antithrombotic evaluation measures like the ATCS should be considered for 
use in future studies as these would have enhanced the comparability and generalisability of our 
warfarin adherence findings. 
Recommendations for Future Research 
Apart from key considerations for future research detailed in the publication and 
discussion chapters (Table 6.), traditional medicine, bodily scarring and peer support are other 
areas identified through the final thesis write-up as recommendations for future research. 
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Table 6: Key recommendations for future research arising from the peer-reviewed, 
published papers, contained within chapters three through six. 
 
Publication Recommendation  
Chapter Three. Short- and 
long-term outcomes after 
valve replacement surgery 
for rheumatic heart disease in 
the South Pacific, conducted 
by a fly-in/fly-out 
humanitarian surgical team: A 
20-year retrospective  study 
for the years 1991 to 2011 
Future research should include prospective data collection 
on important cardiac function parameters and potentially 
preventable mortality and morbidity events. 
Such research should include specific data on 
echocardiography measures, preoperative and postoperative 
functional status, and INR levels over time to enable 
exploration of the relative contribution of these to 
postoperative outcomes. 
Chapter Four. Health-related 
quality of life of patients 
after mechanical valve 
replacement surgery: An 
integrative review 
Greater understanding is required for specific aspects of 
HRQoL, including the effect of age, and in particular for 
patients undergoing mechanical valve replacements in 
developing countries. 
An intention in the original aim of this review was a focus 
on research in developing countries, however, no studies 
conducted in developing countries was found. This 
highlights an important knowledge-gap and future research 
should endeavour to address this. 
Chapter Five. Health-related 
quality of life of patients after 
mechanical valve replacement 
surgery for rheumatic heart 
disease in a developing 
country 
There is an identified need for additional support for 
postoperative VR patients including further investigation 
for patients between the early-term and mid-term time 
points; particularly as mental health was identified as a 
concern at this time.  
Chapter Six. Predictors of 
warfarin non-adherence in 
younger adults after valve 
replacement surgery in the 
South Pacific 
Further research should include objective measurement of 
medication adherence and warfarin knowledge along with a 
collaborative, multidisciplinary approach to identification 
and evaluation of other barriers to adherence.  
The relationship between INR variation and adverse 
outcomes should be addressed in a prospective study. 
 
 
The potential influence of traditional medicine.   
Understanding how people access health care and identifying morbidity is considered one 
of the critical factors in controlling communicable and non-communicable diseases (NCD) in 
resource-poor settings. In one of the largest investigations to date (n = 43,999 from 10,107 
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households), set in West Bengal, India, more than half of NCDs were being treated by 
unqualified practitioners consisting of traditional medicine ('village doctor'), pharmacy sales 
people, and community workers (Kanungo et al., 2015). The people least likely to consult a 
qualified medical practitioner were: younger people (aged five to 18 years); lower caste; working 
in a physically demanding job; and, living in rural regions (Kanungo et al., 2015). 
Traditional medicine and traditional healers are intrinsic to many cultures, particularly 
LMIC, and despite conferring many positive benefits (Singh, 1986; WHO, 2001), they have also 
been recognised as a barrier to early diagnosis and treatment of conditions such as ARF and 
RHD (Roberts et al., 2011; Singh, 1986; Wyber et al., 2014). This is illustrated in data from a 
study conducted in Cameroon, Central Africa, where 45% (n = 208) of patients admitted with 
heart failure, predominantly RHD in origin, had first been treated by a traditional healer 
(Tantchou Tchoumi et al., 2011). The World Heart Federation recommends RHD control 
programmes work to evaluate the role of traditional healers in their particular setting and look to 
ways that control programmes could educate and partner with rational healers in order to 
increase understanding and the need for referral (Wyber et al., 2014).  
In many LMIC, similar to Fiji, subsistence farmers form a large proportion of the 
population, with barter systems in place within and between villages for goods and services, as 
cash-money is scarce (Colquhoun et al., 2016; Wyber et al., 2014). As traditional healers are 
commonly deeply embedded within communities, they are more likely to be consulted for a 
combination of cultural, access and economic reasons (Ahmed & Hossain, 2007; Wyber et al., 
2014).  
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In Fiji, western (allopathic) medicine is considered mainstream and readily utilised, but it 
is also acknowledged that traditional methods often may be first used, particularly in rural areas, 
due to a combination of cultural belief, access and travel cost (Roberts et al., 2011; Singh, 1986). 
Allopathic and traditional medicine co-exist with many allopathic practitioners integrating 
traditional medicine into practice (Roberts et al., 2011). However, there is scant information of 
how village-based traditional medicine use may, or may not, delay diagnosis and/or treatment for 
ARF and RHD, nor how it may be used to aid recovery after VR surgery. A review of the Fiji 
health system by Roberts et al., (2011) suggests that there is a reluctance to openly discuss 
traditional medicine in Fiji due to a perception that this is witchcraft. In my limited experience 
seeking information in this domain in 2016, local medical and nursing staff were more inclined 
to be dismissive describing traditional medicine as "something that occurs in rural areas", is 
"used by uneducated people" and "not relevant to the practice of medicine".  
Whilst little is known regarding the role traditional medicine may play in delays in 
treatment of sore throats, ARF and RHD in Fiji, seeking an understanding of this alongside 
identifying to what degree traditional medicine is used by VR patients would be a first step 
towards understanding if this is an area that should be factored into anti-thrombotic education 
and management, and is a direction for future research.  
The effect of scarring on body image and quality of life. A recognised morbidity after 
surgery involving sternotomy approaches is the formation of abnormal scars that may be 
irregular, keloid, red, itchy and/or disfiguring in some way to the patient (Crossland et al., 2005; 
Kantoch et al., 2006; King, McFetridge-Durdle, LeBlanc, Anzarut, & Tsuyuki, 2009). Evaluating 
how patients feel about their sternal scars is an important consideration for future research in that 
175 
 
they are a visible manifestation of having undergone VR surgery and scar perception may differ 
by cultural background.  
During OHI trips to Fiji, it is not uncommon for parents of unmarried female patients of 
Indian descent to ask me (as point of first contact) and then the surgeons, about ways to ensure 
the sternal incision is as small as possible in an attempt to reduce the size of the scar and, during 
the in-hospital postoperative periods, male i-Taukei patients spend considerable time with each 
other, discussing ways in which they may be able to conceal their scar by having a tribal chest 
tattoo attended. Additionally, in Fiji, apart from visibility, sternal keloid scar formation appears 
common, increasing in size over time.  
Available literature is predominantly on CHD adults who had surgery as children with 
evidence suggesting patient perception of sternal scarring is variable (Crossland et al., 2005; 
Kantoch et al., 2006).  Crossland et al.,(2005) study (n=201) examined young CHD adult 
attitudes towards sternotomy and thoracotomy scarring. Nearly a quarter (24%, n=49) disliked or 
'hated' their scars with significantly more women expressing this (p=0.001) (Crossland et al., 
2005). Kantoch et al., (n=100) investigated a similar group of young adult CHD patients. In their 
study, 60% (n=60) reported their scars troubled them less now, than when they were adolescents 
but 58% (n=58) still considered themselves disfigured with 48% (n=48) continuing to conceal 
their scars. In one-fifth of patients (20%, n=20) scarring was associated with decreased self-
confidence and decreased self-esteem (18%, n=18) Kantoch et al., 2006. 
King, McFetridge-Durdle, LeBlanc, Anzarut, & Tsuyuki, (2009) undertook a descriptive 
study (n=13) of women exploring experience of scarring, and difference in subjective and 
objective scar evaluation. Despite most women perceiving the scar as a trade-off worth the 
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benefits gained from having undergone surgery, they still struggled to live with the reality of the 
scar (King et al., 2009). The overarching finding was the scar being constant reminder of their 
health condition that at times made women feel less attractive (body image) and because of the 
scars visibility, also at times feel publicly judged (stigma)(King et al., 2009).  
Peer support.  
We have made some small steps towards establishing processes for peer-support for our 
Fijian VR patients via closed social media groups  see Table 5.). However, peer-support is an 
important consideration to continue to pursue, particularly given the increased challenges our VR 
patients encounter living in a country with limited resources. Health self-management can infer 
that patients need to deal with chronic care by themselves, however as we have discussed 
previously, it is well recognised that adequate patient support is crucial to better outcomes 
(Dwarswaard, Bakker, van Staa, & Boeije, 2016; Fisher, 2014; Kohut SA, 2014; Munce et al., 
2017). The use of online and social media groups is a readily accessed mechanism where apart 
from the immediacy of online support, group members have access to resources and strategies, 
ranging from in-person social events to more innovative strategies such as photoshoots 
(Appendix I), that can alleviate feelings of aloneness and isolation (Gallagher et al., 2017; 
Merolli, Gray, & Martin-Sanchez, 2013; Santoro, Castelnuovo, Zoppis, Mauri, & Sicurello, 
2015). There do not appear to be any heart valve online support communities that are geared to 
people in LMIC despite philanthropic organisations like WiRED International11 recognising the 
availability of the internet in many low resourced regions, specifically focused on providing 
                                               
11 http://www.wiredinternational.org/ 
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online training programs and educational resources tailored to LMIC conditions and resources. 
Exploring other peer-support strategies for VR patients in Fiji remains a further focus for future 
research.   
Conclusion   
This findings from the research contained in this thesis emphasises the invaluable 
contribution  made by visiting humanitarian teams, like OHI,  in terms of VR surgery provision 
for people affected by RHD in LMICs as exemplified by Fiji, with substantial and ongoing 
benefits for most, evident in mortality, morbidity and HRQoL. However, mortality and morbidity 
outcomes also strongly emphasise the importance of integrating long term outcome reporting 
into surgical programs. This is particularly the case, when these are of a fly-in/fly-out nature 
combined with an absence of specialised in-country service to manage complex lifelong needs 
such as a centralised contact point through which patients can raise VR-specific concerns, 
specialised warfarin clinics, and processes and mechanisms for follow-up such as telephoning 
patients when clinics are missed. The inherent responsibility for international teams performing 
VR surgery in LMIC to ensure pre-existing systems of optimal antithrombotic management and 
follow-up in place before surgery commences is increasingly being explicated in global RHD 
guidelines (Finucane & Wilson, 2013; Wyber et al., 2014). There is an increasing international 
dialogue regarding the responsibilities of international humanitarian teams to conduct long-term 
outcomes follow-up thus the publications of our findings have become very timely (McLennan, 
2014; Molloy et al., 2017; Stone & Olson, 2016; Sykes, 2014).  
Our findings provide unequivocal evidence of the need to work with patients - to give 
them the skills to be experts in their own care - and with Ministries of Health to find innovative 
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ways to increase surveillance across the spectrum of postoperative health-management needs. 
Country-specific preoperative education and continued and evolving postoperative education 
tailored to meet and support the needs of younger VR patients is a clearly identified need. Whilst 
developing tailored warfarin and discharge information sheets are only a small aspect of this 
educational need, development of these demonstrates there are readily achievable steps that can 
actioned 
Fiji is a resource-limited country with competing demands therefore exploring lateral 
ways to increase VR patient surveillance, support and education is a must. Existing personnel, 
such as nurses and clerical staff, could be readily utilised to duplicate existing in-country 
processes that already occur for paediatric patients such as calling patients and parents when 
clinic appointments are missed. Continuing to disseminate outcome findings in the international 
domain along with engagement with the MoH and the wider medical and nursing workforce is 
necessary to ensure that once the surgical team departs, these young people remain prioritised. A 
number of areas and potential strategies for future and post-doctoral research have been 
identified including the most emergent one: that of identifying reasons for disparities in gender 
outcomes and strategies to address this.    
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